

10-16-00

A

00/03/01  
U.S. PTO  
6386

# UTILITY PATENT APPLICATION TRANSMITTAL

## (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
11373ATotal Pages in this Submission  
3**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME**

and invented by:

Tracy Wilson Jian G. Zhang  
 Nicos A. Nicola  
 Douglas J. Hilton  
 Donald Metcalf

JC917 U.S. PTO  
10/13/00

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: 09/051,843

Which is a:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Which is a:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Enclosed are:

**Application Elements**

1.  Filing fee as calculated and transmitted as described below
2.  Specification having 65 pages and including the following:
  - a.  Descriptive Title of the Invention
  - b.  Cross References to Related Applications (if applicable)
  - c.  Statement Regarding Federally-sponsored Research/Development (if applicable)
  - d.  Reference to Microfiche Appendix (if applicable)
  - e.  Background of the Invention
  - f.  Brief Summary of the Invention
  - g.  Brief Description of the Drawings (if drawings filed)
  - h.  Detailed Description
  - i.  Claim(s) as Classified Below
  - j.  Abstract of the Disclosure

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
11373A

Total Pages in this Submission  
3

**Application Elements (Continued)**

3.  Drawing(s) (when necessary as prescribed by 35 USC 113)

a.  Formal Number of Sheets \_\_\_\_\_  
b.  Informal Number of Sheets 24

4.  Oath or Declaration

a.  Newly executed (original or copy)  Unexecuted  
b.  Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)  
c.  With Power of Attorney  Without Power of Attorney

d.  **DELETION OF INVENTOR(S)**

Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).

5.  Incorporation By Reference (usable if Box 4b is checked)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied  
under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby  
incorporated by reference therein.

6.  Computer Program in Microfiche (Appendix)

7.  Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)

a.  Paper Copy  
b.  Computer Readable Copy (identical to computer copy)  
c.  Statement Verifying Identical Paper and Computer Readable Copy

**Accompanying Application Parts**

8.  Assignment Papers (cover sheet & document(s))

9.  37 CFR 3.73(B) Statement (when there is an assignee)

10.  English Translation Document (if applicable)

11.  Information Disclosure Statement/PTO-1449  Copies of IDS Citations

12.  Preliminary Amendment

13.  Acknowledgment postcard

14.  Certificate of Mailing

First Class  Express Mail (Specify Label No.): EL680252395US

**UTILITY PATENT APPLICATION TRANSMITTAL  
(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
11373A

Total Pages in this Submission  
3

**Accompanying Application Parts (Continued)**

15.  Certified Copy of Priority Document(s) *(if foreign priority is claimed)*

16.  Additional Enclosures *(please identify below):*

**Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)**

17.  Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

**Warning**

*An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.*

**UTILITY PATENT APPLICATION TRANSMITTAL  
(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
11373A

Total Pages in this Submission  
3

**Fee Calculation and Transmittal**

**CLAIMS AS FILED**


For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	5	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	2	- 3 =	0	x \$80.00	\$0.00
Multiple Dependent Claims (check if applicable)	<input checked="" type="checkbox"/>				\$270.00
				BASIC FEE	\$710.00
OTHER FEE (specify purpose)					\$0.00
				TOTAL FILING FEE	\$980.00

A check in the amount of **\$980.00** to cover the filing fee is enclosed.  
 The Commissioner is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of **\$980.00** as filing fee.  
 Credit any overpayment.  
 Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.  
 Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: **October 13, 2000**

cc:

  
Leopold Presser  
Registration No.: 19,827

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516)742-4343

10/13/00  
JC8339 U.S. PTO

PATENTS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Tracy A. Wilson, et al.

**Examiner:** Unassigned

**Serial No.:** Unassigned

**Art Unit:** Unassigned

**Filing Date:** Herewith

**Docket:** 11373A

**For:** A NOVEL HAEMOPOIETIN RECEPTOR AND  
GENETIC SEQUENCES ENCODING SAME

**Date:** October 13, 2000

Assistant Commissioner for Patents  
Washington, DC 20231

**PRELIMINARY AMENDMENT**

Sir:

Prior to examination, please amend the above-identified patent application as follows:

**IN THE SPECIFICATION:**

Page 1, after the title, please insert the following:

---


**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

"Express Mail" mailing label number: EL680252395US

Date of Deposit: October 13, 2000

I hereby certify that this New Patent Application and Fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

**Dated:** October 13, 2000

  
Mishelle Mustafa

--CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a divisional of application Serial Number  
09/051,843 filed October 23, 1996.--

Page 1, line 5, insert --FIELD OF THE INVENTION--;

Page 1, line 11, insert --BACKGROUND OF THE INVENTION--;

Page 3, line 9, insert --SUMMARY OF THE INVENTION--;

Page 4, line 12, insert --DETAILED DESCRIPTION OF THE INVENTION--;


Page 31, line 11, delete "In the Figure" and insert therefor --BRIEF  
DESCRIPTION OF THE FIGURES--.

**IN THE CLAIMS:**

Please cancel Claims 1-15 and 20-35 without prejudice, before calculating the  
filing fee of this divisional application.

**REMARKS**

It is respectfully requested that this Preliminary Amendment be entered in this  
application prior to examination. Early and favorable consideration is requested.

Respectfully submitted,  
  
Leopold Presser  
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

PIB:bb

## A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME

5

The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents 10 based on ligand interaction with its receptor.

Bibliographic details of the publications numerically referred to in this specification are collected at the end of the description. Sequence Identity Numbers (SEQ ID NOS.) for the nucleotide and amino acid sequences referred to in the specification are defined following the 15 bibliography.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion 20 of any other integer or group of integers.

The preferred haemopoietin receptor of the present invention is referred to herein as "NR4". The NR4 receptor interacts with IL-13 and is referred to herein as the IL-13 receptor or more particularly the IL-13 receptor  $\alpha$ -chain (IL-13R $\alpha$ ). These terms are used interchangeably 25 throughout the subject specification. The species from which a particular NR4 is derived is given in single letter abbreviation. For example, murine is "M" and human is "H". A recombinant form may have the prefix "r".

The rapidly increasing sophistication of recombinant DNA techniques is greatly facilitating research into the medical and allied health fields. Cytokine research is of particular importance, especially as these molecules regulate the proliferation, differentiation and function of a wide variety of cells. Administration of recombinant cytokines or regulating cytokine function 5 and/or synthesis is increasingly becoming the focus of medical research into the treatment of a range of disease conditions.

Despite the discovery of a range of cytokines and other secreted regulators of cell function, comparatively few cytokines are directly used or targeted in therapeutic regimes. One reason 10 for this is the pleiotropic nature of many cytokines. For example, interleukin (IL)-11 is a functionally pleiotropic molecule (1,2), initially characterized by its ability to stimulate proliferation of the IL-6-dependent plasmacytoma cell line, T11 65 (3). Other biological actions of IL-11 include induction of multipotential haemopoietin progenitor cell proliferation (4,5,6), enhancement of megakaryocyte and platelet formation (7,8,9,10), stimulation of acute 15 phase protein synthesis (11) and inhibition of adipocyte lipoprotein lipase activity (12, 13).

Interleukin-13 (IL-13) is another important cytokine which shares a number of structural characteristics with interleukin-4 (IL-4) [reviewed in 14 and 15]. The genes for IL-4 and IL-13 have a related intron/exon structure and are located close together on chromosome 5 in the 20 human and the syntenic region of chromosome 11 in the mouse (14, 15). At the protein level, IL-4 and IL-13 share approximately 30% amino acid identity, including four cysteine residues. Biologically, IL-13 and IL-4 are also similar, being produced by activated T-cells and acting upon, for example, macrophages to induce differentiation and suppress the production of 25 inflammatory cytokines. Additionally, human IL-13 may act as a co-stimulatory signal for B-cell proliferation and affect immunoglobulin isotype switching (14, 15). The diverse and pleiotropic function of IL-13 and other haemopoietic cytokines makes this group important to study, especially at the level of interaction of the cytokine with its receptors. Manipulation and control of cytokine receptors and of cytokine-receptor interaction is potentially very important 30 in many therapeutic situations, especially where the target cytokine is functionally pleiotropic and it is desired to block certain functions of a target cytokine but not all functions.

Research into IL-13 and its receptor has been hampered due to the inability to clone genetic sequences encoding all or part of the IL-13 receptor. In accordance with the present invention, genetic sequences have now been cloned encoding the IL-13 receptor  $\alpha$ -chain, a receptor subunit which is also shared with the IL-4 receptor. The availability of these genetic sequences 5 permits the development of a range of therapeutic and diagnostic agents capable of modulating or monitoring IL-13 activity as well as the activity of cytokines related to IL-13 at the level of structure or function. In accordance with the present invention, an example of a cytokine related in structure and function to IL-13 is IL-4.

10 Accordingly, one aspect of the present invention is directed to a nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding an haemopoietin receptor from an animal or a derivative of said receptor.

15 More particularly, the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding an animal haemopoietin receptor or a derivative thereof, said receptor capable of interaction with IL-13 or a derivative of IL-13.

20 In a related embodiment, the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding an animal haemopoietin receptor or a derivative thereof, wherein said receptor:

- (i) is capable of interaction with IL-13 or its derivatives; and
- (ii) is capable of interaction with a complex between IL-4 and IL-4 receptor  $\alpha$ -chain.

25 In accordance with these embodiments, a derivative of IL-13 includes agonists, antagonists, antibodies and mimetics.

The present invention is also directed to a nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding an animal IL-13 receptor  $\alpha$ -30 chain or a derivative thereof.

In a related embodiment, the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a component of an animal IL-4 receptor or a derivative thereof.

5 Preferably, the animal is a mammal or a species of bird. Particularly, preferred animals include humans, laboratory test animals (e.g. primates, mice, rabbits, hamsters, guinea pigs), livestock animals (e.g. sheep, goats, horses, pigs, cows, donkeys), companion animals (e.g. dogs, cats), captive wild animals (e.g. foxes, kangaroos, dingoes) and poultry birds (e.g. chickens, geese, ducks) and game birds (e.g. emus, ostriches). Although the present invention is exemplified  
10 with respect to mice and humans, the scope of the subject invention extends to all animals and birds.

The present invention is predicated in part on an ability to identify members of the haemopoietin receptor family on the basis of sequence similarity. Based on this approach, a  
15 genetic sequence was identified in accordance with the present invention which encodes a haemopoietin receptor. The expressed genetic sequence is referred to herein as "NR4". In accordance with the present invention, NR4 has an apparent molecular mass when synthesised by transfected COS cells of from about 50,000 to about 70,000 daltons, and more preferably from about 55,000 to about 65,000 daltons. NR4 binds to IL-13 specifically and with low  
20 affinity and is considered, therefore, to be an IL-13 receptor  $\alpha$ -chain. Accordingly, the terms "NR4" and "IL-13 receptor  $\alpha$ -chain" (or "IL-13 R $\alpha$ ") are used interchangeably throughout the subject specification. Furthermore, IL-13 binding to its receptor has been found to be competitively inhibited by IL-4 or a component thereof in cells which express the IL-4 receptor  
25  $\alpha$ -chain and this may provide a method for controlling IL-13-receptor interaction and will also provide a basis for the preparation and construction of mimetics.

Another aspect of the present invention provides a nucleic acid molecule comprising a sequence of nucleotides encoding IL-13 receptor  $\alpha$ -chain having an amino acid sequence as set forth in SEQ ID NO:2 or having at least about 50% similarity to all or part thereof. Preferably, the  
30 percentage similarity is at least about 60%, more preferably at least about 70%, even more

- 5 -

preferably at least about 80-85% and still even more preferably at least about 90-95% or greater. The reference to all or part of a sequence is intended to include defining a hybrid molecule comprising parts of two receptors. It is not intended to encompass single amino acids.

5 A further embodiment of the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides encoding the IL-13 receptor  $\alpha$ -chain and having a nucleotide sequence substantially as set forth in SEQ ID NO:1 or having at least about 50% similarity to all or part thereof. Preferably, the percentage similarity is at least about 60%, more preferably at least about 70%, even more preferably at least about 80-85% and still even  
10 more preferably at least about 90-95% or greater.

Still another aspect of the present invention provides a nucleic acid molecule comprising a sequence of nucleotides encoding IL-13 receptor  $\alpha$ -chain having an amino acid sequence as set forth in SEQ ID NO:4 or having at least about 50% similarity to all or part thereof. Preferably,  
15 the percentage similarity is at least about 60%, more preferably at least about 70%, even more preferably at least about 80-85% and still even more preferably at least about 90-95% or greater.

Yet still a further embodiment of the present invention contemplates a nucleic acid molecule  
20 comprising a sequence of nucleotides encoding the IL-13 receptor  $\alpha$ -chain and having a nucleotide sequence substantially as set forth in SEQ ID NO:3 or having at least about 50% similarity to all or part thereof. Preferably, the percentage similarity is at least about 60%, more preferably at least about 70%, even more preferably at least about 80-85% and still even more preferably at least about 90-95% or greater.

25

Accordingly, the present invention extends to the sequence of nucleotides set forth in SEQ ID NO:1 or 3 or the sequence of amino acids set forth in SEQ ID NO:2 or 4 or single or multiple nucleotide or amino acid substitutions, deletions and/or additions thereto.

The present invention further extends to nucleic acid molecules capable of hybridising under low stringency conditions to the nucleotide sequence set forth in SEQ ID NO:1 or 3 or a complementary form thereof.

5 The present invention extends to recombinant haemopoietin receptors and in particular recombinant NR4 and recombinant hybrids containing NR4. Preferred recombinant polypeptides interact with IL-13 with low affinity and even more preferably with high affinity.

In a particularly preferred embodiment polypeptide has at least two of the following 10 characteristics:

- (i) comprises an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4 or having at least about 50% similarity to all or part thereof;
- (ii) is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:3 or having at least about 50% similarity to all or part thereof;
- 15 (iii) interacts with IL-13 or its derivatives with at least low affinity; and
- (iv) has a molecular weight of from about 50,000 to about 70,000 daltons as determined by Western blot analysis when expressed in COS cells.

In a related embodiment, the polypeptide has at least three of the following characteristics:

- 20 (i) comprises an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4 or having at least about 50% similarity to all or part thereof;
- (ii) is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:3 or having at least about 50% similarity to all or part thereof;
- (iii) interacts with IL-13 or its derivatives with at least low affinity;
- 25 (iv) has a molecular weight of from about 50,000 to about 70,000 daltons as determined by Western blot analysis when expressed in COS cells;
- (v) comprises an amino acid sequence derived from IL-4 receptor  $\alpha$ -chain; and
- (vi) is capable of interaction with IL-13 which is competitively inhibited by IL-4 in cells which express an IL-4 receptor  $\alpha$ -chain.

Reference herein to "recombinant haemopoietin receptor", "NR4", "IL-13 receptor" or "IL-13" receptor  $\alpha$ -chain" includes reference to derivatives thereof such as parts, fragments, portions, homologues, hybrids or analogues thereof. The derivatives may be functional or not or may be non-functional but immunologically interactive with antibodies to all or part of the receptor.

5 Derivatives of the receptor also cover agonists or antagonists of receptor-ligand interaction. Function is conveniently defined by an ability of NR4 to interact with IL-13 or its derivatives or for soluble NR4 to compete with IL-13-induced activities of certain cells.

Particularly preferred derivatives contemplated by the present invention include derivatives of

10 IL-13 receptor  $\alpha$ -chain which are capable of binding IL-13 with high affinity or with IL-13 and IL-4 with high affinity; derivatives also encompass chimeric molecules such as between IL-13 receptor  $\alpha$ -chain and, for example, IL-4 receptor  $\alpha$ -chain which also bind IL-13 with high affinity.

15 Other fusion or chimeric molecules contemplated by the present invention include those between NR4 and members of the haemopoietin receptor family, receptor tyrosine kinases, TNF/NGF receptors and G protein-coupled receptors. For example, chimeras may be between NR4 and IL-13 binding protein, IL-4 receptor  $\alpha$ -chain, IL-2 receptor  $\gamma$ -chain or receptors for other cytokines involved or implicated in asthma and allergy such as IL-5. Other important 20 chimeras include NR4 and immunoglobulins or other molecules which allow targeting of NR4 to particular cells or tissues, NR4 and toxins and NR4 and growth factors.

Reference herein to a low stringency at 42°C includes and encompasses from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt 25 for hybridisation, and at least about 1M to at least about 2M salt for washing conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which 30 includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and

from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.

Yet another aspect of the present invention provides a nucleic acid molecule comprising a sequence of nucleotides which encodes or is complementary to a sequence which encodes an IL-13 receptor  $\alpha$ -chain, said nucleic acid molecule having a nucleotide sequence substantially as set forth in SEQ ID NO:1 or 3 or a nucleic acid molecule which encodes a structurally similar IL-13 receptor  $\alpha$ -chain or a derivative thereof and which is capable of hybridising to the nucleotide sequence substantially as set forth in SEQ ID NO:1 or 3 or a complementary form 10 thereof under low stringency conditions.

Still yet another aspect of the present invention is directed to a nucleic acid molecule comprising a sequence of nucleotides which encodes or is complementary to a sequence which encodes the IL-13 receptor  $\alpha$ -chain having an amino acid sequence substantially as set forth in 15 SEQ ID NO:2 or 4 or comprises a nucleotide sequence coding for an amino acid sequence having at least about 50% similarity to the sequence set forth in SEQ ID NO:2 or 4 and is capable of hybridising to the sequence set forth in SEQ ID NO:1 or 3 under low stringency conditions.

20 The nucleic acid molecules contemplated by the present invention are generally in isolated form and may be single or double stranded, linear or closed circle DNA (e.g. genomic DNA), cDNA or mRNA or combinations thereof such as in the form of DNA:RNA hybrids. In a particularly preferred embodiment, the nucleic acid molecules are in vectors and most preferably expression vectors to enable expression in a suitable host cell. Particularly useful host cells include 25 prokaryotic cells, mammalian cells, yeast cells and insect cells. The cells may also be in the form of a cell line.

According to this aspect of the present invention there is provided an expression vector comprising a nucleic acid molecule encoding the IL-13 receptor  $\alpha$ -chain as hereinbefore 30 described, said expression vector capable of expression in a particular host cell.

- 9 -

Another aspect of the present invention contemplates a recombinant polypeptide comprising a sequence of amino acids substantially as set forth in SEQ ID NO:2 or 4 or having at least about 50% similarity to all or part thereof. Preferably, the percentage similarity is at least about 60%, more preferably at least about 70%, even more preferably at least about 80-85% and still 5 even more preferably at least about 90-95% or greater.

The recombinant polypeptide contemplated by the present invention includes, therefore, components, parts, fragments, derivatives, homologues or analogues of the IL-13 receptor  $\alpha$ -chain and is preferably encoded by a nucleotide sequence substantially set forth in SEQ ID 10 NO:1 or 3 or a molecule having at least about 50% similarity to all or part thereof or a molecule capable of hybridising to the nucleotide sequence set forth in SEQ ID NO:1 or 3 or a complementary form thereof. The recombinant molecule may be glycosylated or non-glycosylated. When in glycosylated form, the glycosylation may be substantially the same as naturally occurring IL-13 receptor  $\alpha$ -chain or may be a modified form of glycosylation. 15 Altered or differential glycosylation states may or may not affect binding activity of the IL-13 receptor  $\alpha$ -chain.

The recombinant IL-13 receptor  $\alpha$ -chain may be in soluble form or may be expressed on a cell surface or conjugated or fused to a solid support or another molecule.

20 The present invention further contemplates a method for producing a recombinant polypeptide having at least two of the following characteristics:

- (i) comprises an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4 or having at least about 50% similarity thereto;
- 25 (ii) is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:3 or having at least about 50% similarity thereto;
- (iii) interacts with IL-13 or its derivatives with at least low affinity; and
- (iv) has a molecular weight of from about 50,000 to about 70,000 daltons as determined by Western blot analysis when expressed in COS cells,

30

- 10 -

said method comprising culturing cells comprising the genetic constructs of the present invention for a time and under conditions sufficient to express the nucleic acid molecule in said genetic construct to produce a recombinant polypeptide and isolating said recombinant polypeptide.

5

Another embodiment provides a method of producing a recombinant polypeptide having at least three of the following characteristics:

- (i) comprises an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4 or having at least about 50% similarity to all or part thereof;
- 10 (ii) is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:3 or having at least about 50% similarity to all or part thereof;
- (iii) interacts with IL-13 or its derivatives with at least low affinity;
- (iv) has a molecular weight of from about 50,000 to about 70,000 daltons as determined by Western blot analysis when expressed in COS cells;
- 15 (v) comprises an amino acid sequence derived from IL-4 receptor  $\alpha$ -chain; and
- (vi) is capable of interaction with IL-13 which is competitively inhibited by IL-4 in cells which express an IL-4 receptor  $\alpha$ -chain.

20 said method comprising culturing cells comprising the fusion genetic constructs according to the present invention for a time and under conditions sufficient to express the nucleic acid molecule in said fusion genetic constructs to produce a recombinant polypeptide and isolating said recombinant polypeptide.

The present invention further extends to cells such as animal cells which express the above-mentioned recombinant polypeptides.

25

Another embodiment of the present invention provides chemical analogues of the recombinant IL-13 receptor  $\alpha$ -chain.

As stated above, the present invention further contemplates a range of derivatives of NR4. Derivatives include fragments, parts, portions, mutants, hybrids (including fusion and chimeric molecules), homologues and analogues of the NR4 polypeptide and corresponding genetic sequence. In one preferred embodiment, the derivatives bind IL-13 with high affinity. Other 5 preferred derivatives act as agonists, antagonist or mimetics. Derivatives also include single or multiple amino acid substitutions, deletions and/or additions to NR4 or single or multiple nucleotide substitutions, deletions and/or additions to the genetic sequence encoding NR4. "Additions" to amino acid sequences or nucleotide sequences include fusions with other peptides, polypeptides or proteins or fusions to nucleotide sequences. Reference herein to 10 "NR4" includes reference to all derivatives thereof including functional derivatives or "NR4" immunologically interactive derivatives. The present invention also extends to hybrid molecules, such as between murine or human NR4 or derivatives thereof. A particularly preferred hybrid comprises NR4 and IL-4 receptor  $\alpha$ -chain.

15 Analogues of NR4 contemplated herein include, but are not limited to, modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogues.

20 Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH<sub>4</sub>; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylolation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH<sub>4</sub>.

25

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

- 12 -

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

10

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetrinitromethane to form a 3-nitrotyrosine derivative.

15

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis 20 include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 1.

25

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having  $(CH_2)_n$  spacer groups with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group 30 specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH).

In addition, peptides can be conformationally constrained by, for example, incorporation of C<sub>α</sub> and N<sub>α</sub>-methylamino acids, introduction of double bonds between C<sub>α</sub> and C<sub>β</sub> atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

These types of modifications may be important to stabilise NR4 if administered to an individual or for use as a diagnostic reagent

- 10 The present invention further contemplates chemical analogues of NR4 capable of acting as antagonists or agonists of NR4 or which can act as functional analogues of NR4. Chemical analogues may not necessarily be derived from NR4 but may share certain conformational similarities. Alternatively, chemical analogues may be specifically designed to mimic certain physiochemical properties of NR4. Chemical analogues may be chemically synthesised or may
- 15 be detected following, for example, natural product screening.

The identification of NR4 permits the generation of a range of therapeutic molecules capable of modulating expression of NR4 or modulating the activity of NR4. Modulators contemplated by the present invention includes agonists and antagonists of NR4 gene expression or NR4 protein activity. Antagonists of NR4 gene expression include antisense molecules, ribozymes and co-suppression molecules. Agonists include molecules which increase promoter ability or interfere with negative regulatory mechanisms. Agonists of NR4 protein include antibodies, ligands and mimetics. Antagonists of NR4 include antibodies and inhibitor peptide fragments. Where a cell co-expresses NR4 and IL-4 receptor  $\alpha$ -chain, agonists and antagonists may target

- 25 the IL-4 receptor  $\alpha$ -chain.

TABLE 1

Non-conventional amino acid	Code	Non-conventional amino acid	Code
5 <b>α</b> -aminobutyric acid	Abu	L-N-methylalanine	Nmala
<b>α</b> -amino- <b>α</b> -methylbutyrate	Mgabu	L-N-methylarginine	Nmarg
aminocyclopropane- carboxylate	Cpro	L-N-methylethylasparagine	Nma..
10 aminoisobutyric acid	Aib	L-N-methylethylaspartic acid	Nmasp
aminonorbornyl- carboxylate	Norb	L-N-methylcysteine	Nmcys
cyclohexylalanine		L-N-methylglutamine	Nmgln
cyclopentylalanine	Cpen	L-N-methylglutamic acid	Nmglu
15 D-alanine	Dal	Chexa L-N-methylhistidine	Nmhis
D-arginine	Darg	L-N-methylisoleucine	Nmile
D-aspartic acid	Dasp	L-N-methylleucine	Nmleu
D-cysteine	Dcys	L-N-methyllysine	Nmlys
D-glutamine	Dgln	L-N-methylmethionine	Nmmet
20 D-glutamic acid	Dglu	L-N-methylnorleucine	Nmnle
D-histidine	Dhis	L-N-methylnorvaline	Nmnva
D-isoleucine	Dile	L-N-methylornithine	Nmorn
D-leucine	Dleu	L-N-methylphenylalanine	Nmphe
D-lysine	Dlys	L-N-methylproline	Nmpro
25 D-methionine	Dmet	L-N-methylserine	Nmser
D-ornithine	Dorn	L-N-methylthreonine	Nmthr
D-phenylalanine	Dphe	L-N-methyltryptophan	Nmtrp
D-proline	Dpro	L-N-methyltyrosine	Nmtyr
D-serine	Dser	L-N-methylvaline	Nmval
30 D-threonine	Dthr	L-N-methylethylglycine	Nmetg
		L-N-methyl-t-butylglycine	Nmtbug
		L-norleucine	Nle

D-tryptophan	Dtrp	L-norvaline	Nva
D-tyrosine	Dtyr	$\alpha$ -methyl-aminoisobutyrate	Maib
D-valine	Dval	$\alpha$ -methyl- $\gamma$ -aminobutyrate	Mgabu
D- $\alpha$ -methylalanine	Dmala	$\alpha$ -methylcyclohexylalanine	Mchexa
5 D- $\alpha$ -methylarginine	Dmarg	$\alpha$ -methylcyclopentylalanine	Mcpen
D- $\alpha$ -methylasparagine	Dmasn	$\alpha$ -methyl- $\alpha$ -naphthylalanine	Manap
D- $\alpha$ -methylaspartate	Dmasp	$\alpha$ -methylpenicillamine	Mpen
D- $\alpha$ -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
D- $\alpha$ -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
10 D- $\alpha$ -methylhistidine	Dmhis	N-(3-aminoopropyl)glycine	Norn
D- $\alpha$ -methylisoleucine	Dmile	N-amino- $\alpha$ -methylbutyrate	Nmaabu
D- $\alpha$ -methylleucine	Dmleu	$\alpha$ -naphthylalanine	Anap
D- $\alpha$ -methyllysine	Dmlys	N-benzylglycine	Nphe
D- $\alpha$ -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
15 D- $\alpha$ -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
D- $\alpha$ -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
D- $\alpha$ -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
D- $\alpha$ -methylserine	Dmser	N-cyclobutylglycine	Ncbut
D- $\alpha$ -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
20 D- $\alpha$ -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
D- $\alpha$ -methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
D- $\alpha$ -methylvaline	Dmval	N-cyclododecylglycine	Ncdod
D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
25 D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
30 D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser

- 16 -

D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
D-N-methylleucine	Dnmleu	N-(3-indolylethyl)glycine	Nhtrp
D-N-methyllysine	Dnmlys	N-methyl- $\gamma$ -aminobutyrate	Nmgabu
N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnammet
5 D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
10 D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
D-N-methyltyrosine	Dnmtyr	N-methyl- $\alpha$ -naphthylalanine	Nmanap
D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
$\gamma$ -aminobutyric acid	Gabu	N-( <i>p</i> -hydroxyphenyl)glycine	Nhtyr
L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
15 L-ethylglycine	Etg	penicillamine	Pen
L-homophenylalanine	Hphe	L- $\alpha$ -methylalanine	Mala
L- $\alpha$ -methylarginine	Marg	L- $\alpha$ -methylasparagine	Masn
L- $\alpha$ -methylaspartate	Masp	L- $\alpha$ -methyl- <i>t</i> -butylglycine	Mtbug
L- $\alpha$ -methylcysteine	Mcys	L-methylethylglycine	Metg
20 L- $\alpha$ -methylglutamine	Mgln	L- $\alpha$ -methylglutamate	Mglu
L- $\alpha$ -methylhistidine	Mhis	L- $\alpha$ -methylhomophenylalanine	Mhphe
L- $\alpha$ -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
L- $\alpha$ -methylleucine	Mleu	L- $\alpha$ -methyllysine	Mlys
L- $\alpha$ -methylmethionine	Mmet	L- $\alpha$ -methylnorleucine	Mnle
25 L- $\alpha$ -methylnorvaline	Mnva	L- $\alpha$ -methylornithine	Morn
L- $\alpha$ -methylphenylalanine	Mphe	L- $\alpha$ -methylproline	Mpro
L- $\alpha$ -methylserine	Mser	L- $\alpha$ -methylthreonine	Mthr
L- $\alpha$ -methyltryptophan	Mtrp	L- $\alpha$ -methyltyrosine	Mtyr
L- $\alpha$ -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe

- 17 -

N-(N-(2,2-diphenylethyl) carbamylmethyl)glycine  
1-carboxy-1-(2,2-diphenyl- ethylamino)cyclopropane

N-(N-(3,3-diphenylpropyl) carbamylmethyl)glycine

Nnbhe

5

Other derivatives contemplated by the present invention include a range of glycosylation variants from a completely unglycosylated molecule to a modified glycosylated molecule. Altered glycosylation patterns may result from expression of recombinant molecules in 10 different host cells.

Another embodiment of the present invention contemplates a method for modulating expression of the NR4 gene in a human, said method comprising contacting the NR4 gene encoding NR4 with an effective amount of a modulator of NR4 expression for a time and 15 under conditions sufficient to up-regulate or down-regulate or otherwise modulate expression of NR4. A nucleic acid molecule encoding NR4 or a derivative thereof may also be introduced into a cell to enhance or alter NR4 related activities of that cell including replacing an endogenous NR4 gene sequence which may, for example, be defective or carry one or more undesired mutations. Conversely, NR4 antisense sequences (or sense sequences for co- 20 suppression) such as oligonucleotides may be introduced to decrease NR4-related activities of any cell expressing the endogenous NR4 gene. Ribozymes may also be used.

Another aspect of the present invention contemplates a method of modulating activity of NR4 in a human, said method comprising administering to said mammal a modulating effective 25 amount of a molecule for a time and under conditions sufficient to increase or decrease NR4 activity. The molecule may be a proteinaceous molecule or a chemical entity and may also be a derivative of NR4 or its ligand or a chemical analogue or truncation mutant of NR4 or its ligand.

For example, IL-13 and IL-4 have been implicated in the modulation of immune responses and in the production of IgE which is the immunoglobulin isotype associated with allergic or atopic diseases such as asthma. Modulating interactions between IL-13/IL-4 and their receptors may be important in treating inflammatory conditions such as allergic conditions.

5 Elevated levels of IL-4/IL-13 and IgE are also important in diseases such as nephrotic syndrome, vernal and keratoconjunctivitis. Other diseases, the treatment of which is contemplated herein include bronchial asthma, perennial rhinitis and atopic dermatitis. Other disease conditions for which modulation of IL-13-receptor interaction may be important includes those conditions where IL-13 induces cytokine formation which in turn are involved  
10 in onset, progression and/or severity of diseases. Similarly, modulating IL-4-receptor interaction may also be important in controlling disease conditions. For example, some cancers may be exacerbated by the cytokine IL-13 or IL-4 which induce repressive immune effects or effector molecules which in turn reduce the body's ability to respond to the growth of the cancers.

15

Accordingly, the present invention contemplates a pharmaceutical composition comprising NR4 or a derivative thereof or a modulator of NR4 expression or NR4 activity and one or more pharmaceutically acceptable carriers and/or diluents. These components are referred to as the "active ingredients".

20

In this regard there is provided a pharmaceutical composition comprising a recombinant haemopoietin receptor as hereinbefore described or a ligand (e.g. IL-13) binding portion thereof and one or more pharmaceutically acceptable carriers and/or diluents.

25 In another embodiment, there is provided a pharmaceutical composition comprising a ligand (e.g. IL-13) to the recombinant haemopoietin receptor as hereinbefore described and one or more pharmaceutically acceptable carriers and/or diluents.

Still a further aspect of the present invention contemplates a method of treatment of an animal comprising administering to said animal a treatment effective amount of a recombinant haemopoietin receptor as hereinbefore described or a ligand binding portion thereof or a ligand (e.g. IL-13) to said haemopoietic receptor for a time and under conditions sufficient for said treatment to be substantially effected or the conditions to be substantially ameliorated.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion or may be in the form of a cream or other form suitable for topical application. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as licithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously

sterile-filtered solution thereof.

When the active ingredients are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in 5 hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The 10 percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions in such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 ug and 2000 mg of active 15 compound.

The tablets, troches, pills, capsules and the like may also contain the components as listed hereafter: A binder such as gum, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; 20 a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules 25 may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound(s) may be incorporated into sustained-release 30 preparations and formulations.

- 21 -

The present invention also extends to forms suitable for topical application such as creams, lotions and gels.

Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

10

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired.

The principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore disclosed. A unit dosage form can, for example, contain the principal active compound in amounts ranging from 0.5  $\mu$ g to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.5  $\mu$ g to about 2000 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

- 22 -

The pharmaceutical composition may also comprise genetic molecules such as a vector capable of transfecting target cells where the vector carries a nucleic acid molecule capable of modulating NR4 expression or NR4 activity. The vector may, for example, be a viral vector.

5

Still another aspect of the present invention is directed to antibodies to NR4 and its derivatives or its ligands (e.g. IL-13). Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to NR4 or may be specifically raised to NR4 or derivatives thereof. In the case of the latter, NR4 or its derivatives may first need to be 10 associated with a carrier molecule. The antibodies and/or recombinant NR4 or its derivatives of the present invention are particularly useful as therapeutic or diagnostic agents.

For example, NR4 and its derivatives can be used to screen for naturally occurring antibodies to NR4. These may occur, for example in some autoimmune diseases. Alternatively, specific 15 antibodies can be used to screen for NR4. Techniques for such assays are well known in the art and include, for example, sandwich assays and ELISA. Knowledge of NR4 levels and/or IL-13 levels may be important for diagnosis of certain cancers or a predisposition to cancers or for monitoring certain therapeutic protocols. In particular, it may be important to monitor an IgE response or levels of IL-13 or IL-4 or both which in turn have an effect on the immune 20 system.

Antibodies to NR4 of the present invention may be monoclonal or polyclonal. Alternatively, fragments of antibodies may be used such as Fab fragments. Furthermore, the present invention extends to recombinant and synthetic antibodies and to antibody hybrids. A 25 "synthetic antibody" is considered herein to include fragments and hybrids of antibodies. The antibodies of this aspect of the present invention are particularly useful for immunotherapy and may also be used as a diagnostic tool for assessing the receptor or receptor-ligand interaction or monitoring the program of a therapeutic regimen.

For example, specific antibodies can be used to screen for NR4 proteins. The latter would be important, for example, as a means for screening for levels of NR4 in a cell extract or other biological fluid or purifying NR4 made by recombinant means from culture supernatant fluid. Techniques for the assays contemplated herein are known in the art and include, for example, 5 sandwich assays and ELISA.

It is within the scope of this invention to include any second antibodies (monoclonal, polyclonal or fragments of antibodies or synthetic antibodies) directed to the first mentioned antibodies discussed above. Both the first and second antibodies may be used in detection 10 assays or a first antibody may be used with a commercially available anti-immunoglobulin antibody. An antibody as contemplated herein includes any antibody specific to any region of NR4.

Both polyclonal and monoclonal antibodies are obtainable by immunization with the receptor 15 and either type is utilizable for immunoassays. The methods of obtaining both types of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of NR4, or antigenic parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoabsorbent techniques. Although antibodies produced by this method are 20 utilizable in virtually any type of immunoassay, they are generally less favoured because of the potential heterogeneity of the product.

The use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product. The 25 preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art.

Another aspect of the present invention contemplates a method for detecting NR4 in a biological sample from a subject said method comprising contacting said biological sample with an antibody specific for NR4 or its derivatives or homologues for a time and under conditions sufficient for an antibody-NR4 complex to form, and then detecting said complex.

5

The presence of NR4 may be accomplished in a number of ways such as by Western blotting and ELISA procedures. A wide range of immunoassay techniques are available as can be seen by reference to US Patent Nos. 4,016,043, 4,424,279 and 4,018,653. These, of course, includes both single-site and two-site or "sandwich" assays of the non-competitive types, as

10 well as in the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target.

Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, 15 and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabelled antibody is immobilized on a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-antigen complex, a second antibody specific to the antigen, labelled with a reporter molecule capable of producing a 20 detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labelled antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known 25 amounts of hapten. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. In accordance with the present invention the sample is one which might contain NR4 including cell extract, tissue biopsy or possibly serum, saliva, mucosal secretions, 30 lymph, tissue fluid and respiratory fluid. The sample is, therefore, generally a biological

sample comprising biological fluid, cell extract, bone marrow or lymph, tissue extract (e.g. from kidney, liver, spleen, etc), fermentation fluid and supernatant fluid such as from a cell culture and cell conditioned medium.

5 In the typical forward sandwich assay, a first antibody having specificity for the NR4 or antigenic parts thereof, is either covalently or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for

10 conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes) and under suitable conditions (e.g. 25°C) to allow binding of any subunit present

15 in the antibody. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of the hapten. The second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to the hapten.

20 An alternative method involves immobilizing the target molecules in the biological sample and then exposing the immobilized target to specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-

25 first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.

By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of

30 antigen-bound antibody. Detection may be either qualitative or quantitative. The most

commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules.

In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however,

5 a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. Examples of suitable enzymes include

10 alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the first antibody hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react

15 with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present in the sample. "Reporter molecule" also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.

20 Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. As in the EIA, the

25 fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such 30 as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.

- 27 -

Another form of assay involves cells capable of expressing NR4 and IL-4 receptor  $\alpha$ -chain. For example, if IL-4 receptor  $\alpha$ -chain and NR4 are co-expressed on cells, such as COS cells, then IL-13 binds to NR4 with a high affinity in the presence of IL-4.

5 Although not intending to limit the present invention to any one theory or mode of action, when NR4 and the IL-4 receptor are expressed in the same cell, they contribute to the formation of both IL-4 and IL-13 receptors. In the case of IL-4, binding occurs first through the IL-4 receptor  $\alpha$ -chain and then NR4 interacts with this complex. In the case of IL-13, binding occurs first to NR4 and then IL-4 receptor  $\alpha$ -chain interacts with the complex to form 10 a high affinity receptor capable of signal transduction. The consequences of co-expression of NR4 and IL-4 receptor  $\alpha$ -chain is that IL-4 and IL-13 can compete with each other for binding to the IL-4 receptor  $\alpha$ -chain and NR4.

Based on this behaviour, it would appear that any protein or small molecule that prevented IL-15 4 or IL-13 forming cell surface complexes containing both receptor components may be antagonistic. Such molecules may prevent interaction of the cytokine with its low affinity receptor. For example, soluble IL-13BP can prevent IL-13 interaction with NR4. Likewise, soluble IL-4 receptor  $\alpha$ -chain can prevent binding of IL-4 to cell surface IL-4 receptor  $\alpha$ -chain. These reagents would be antagonists that were specific for IL-4 or IL-13.

20

By extension, because of its very low affinity, soluble NR4 is a very inefficient IL-13 antagonist. If a soluble NR4 mutant is selected that now binds to IL-4 and also binds to IL-13 with higher affinity, this would be a useful antagonist of both IL-4 and IL-13.

25 An alternative to use of soluble receptor, is to generate a panel of monoclonal antibodies to NR4. If an antibody is obtained which prevents interaction of NR4 with the IL-4 receptor  $\alpha$ -chain, a critical event in formation of both functional IL-4 receptor and functional IL-13 receptors, then again the action of both cytokines is inhibited.

30

- 28 -

In a one particular embodiment the present invention contemplates a method for monitoring the level of IL-4 in a biological sample said method comprising incubating said biological sample with cells which express NR4 and IL-4 receptor  $\alpha$ -chain together with an effective amount of IL-13 to competitively inhibit IL-4 binding to its receptor and determining the extent of competitive inhibition.

In a related embodiment the present invention contemplates a method for monitoring the level of IL-13 in a biological sample said method comprising incubating said biological sample with cells which express NR4 and IL-4 receptor  $\alpha$ -chain together with an effective amount of IL-4

10 to competitively inhibit IL-13 binding to its receptor and determining the extent of competitive inhibition.

Preferably, the cytokines are labelled with a reporter molecule as described above.

15 The biological sample includes but is not limited to blood, serum, plasma, tissue fluid, tissue extract, lymph, T cells or extracts thereof, culture supernatant and conditioned medium.

The present invention also contemplates genetic assays such as involving PCR analysis to detect NR4 gene or its derivatives. Alternative methods or methods used in conjunction 20 include direct nucleotide sequencing or mutation scanning such as single stranded conformation polymorphisms analysis (SSCP) as specific oligonucleotide hybridisation, as methods such as direct protein truncation tests. Such genetic tests may be important, for example, in genetic screening of animals (e.g. humans) for non-expression or substantial absence of expression or expression of mutant forms of NR4 leading to disease conditions.

25

The nucleic acid molecules of the present invention may be DNA or RNA. When the nucleic acid molecule is in DNA form, it may be genomic DNA or cDNA. RNA forms of the nucleic acid molecules of the present invention are generally mRNA.

Although the nucleic acid molecules of the present invention are generally in isolated form, they may be integrated into or ligated to or otherwise fused or associated with other genetic molecules such as vector molecules and in particular expression vector molecules. Vectors and expression vectors are generally capable of replication and, if applicable, expression in 5 one or both of a prokaryotic cell or a eukaryotic cell. Preferably, prokaryotic cells include *E. coli*, *Bacillus sp* and *Pseudomonas sp*. Preferred eukaryotic cells include yeast, fungal, mammalian and insect cells.

Accordingly, another aspect of the present invention contemplates a genetic construct 10 comprising a vector portion and a mammalian and more particularly a human NR4 gene portion, which NR4 gene portion is capable of encoding an NR4 polypeptide or a functional or immunologically interactive derivative thereof.

Preferably, the NR4 gene portion of the genetic construct is operably linked to a promoter on 15 the vector such that said promoter is capable of directing expression of said NR4 gene portion in an appropriate cell.

In addition, the NR4 gene portion of the genetic construct may comprise all or part of the gene fused to another genetic sequence such as a nucleotide sequence encoding glutathione-S- 20 transferase or part thereof or a cytokine or another haemopoietic receptor. Hybrid receptor molecules are particularly useful in the development of multi functional therapeutic and diagnostic agents.

The present invention extends to such genetic constructs and to prokaryotic or eukaryotic cells 25 comprising same.

The present invention also extends to any or all derivatives of NR4 including mutants, part, fragments, portions, homologues and analogues or their encoding genetic sequence including single or multiple nucleotide or amino acid substitutions, additions and/or deletions to the 30 naturally occurring nucleotide or amino acid sequence.

The NR4 and its genetic sequence of the present invention will be useful in the generation of a range of therapeutic and diagnostic reagents and will be especially useful in the detection of a corresponding ligand. For example, recombinant NR4 may be bound or fused to a reporter molecule capable of producing an identifiable signal, contacted with a biological sample 5 putatively containing a ligand and screening for binding of the labelled NR4 to the ligand. Alternatively, labelled NR4 may be used to screen expression libraries of putative ligand genes or functional parts thereof.

In another embodiment, the NR4 is first immobilised. According to this embodiment, there 10 is provided a method comprising contacting a biological sample containing a putative ligand with said haemopoietic receptor or a ligand binding portion thereof immobilised to a solid support for a time and under conditions sufficient for a complex to form between said receptor and said ligand if said ligand is present in said biological sample, eluting bound ligand and isolating same.

15 Soluble NR4 polypeptides as well as various hybrids are also contemplated to be useful in the treatment of disease, injury or abnormality in the nervous system, e.g. in relation to central or peripheral nervous system to treat Cerebral Palsy, trauma induced paralysis, vascular ischaemia associated with stroke, neuronal tumours, motoneurone disease, Parkinson's disease, 20 Huntington's disease, Alzheimer's disease, Multiple Sclerosis, peripheral neuropathies associated with diabetes, heavy metal or alcohol toxicity, renal failure and infectious diseases such as herpes, rubella, measles, chicken pox, HIV or HTLV-1. The NR4 polypeptides and hybrids may also be important for regulating cytokine activity and/or modulating haemopoiesis. They are also important for treating allergic or atopic conditions as well as other inflammatory 25 conditions such as rheumatoid arthritis.

As stated above, the NR4 or its ligand of the present invention or their functional derivatives may be provided in a pharmaceutical composition together with one or more pharmaceutically acceptable carriers and/or diluents. In addition, the present invention contemplates a method 30 of treatment comprising the administration of an effective amount of NR4 of the present

- 31 -

invention. The present invention also extends to antagonists and agonists of NR4 and/or its ligand and their use in therapeutic compositions and methodologies.

A further aspect of the present invention contemplates the use of NR4 or its functional derivatives in the manufacture of a medicament for the treatment of NR4 mediated conditions defective or deficient.

The present invention is further described by the following non-limiting Figures and Examples

10

In the Figures:

Figure 1 is a representation of the nucleotide [SEQ ID NO:1] and predicted amino acid [SEQ ID NO:2] sequence of murine NR4. The untranslated region is shown in lower case and the 15 translated region in upper case. The conventional one-letter code for amino acids is employed, potential asparagine linked glycosylation sites are underlined and the conserved cysteine residues and WSXWS motif of haemopoietin receptor family members are shown in bold. The predicted signal sequence is underlined in bold while the transmembrane domain is underlined with dashes. The sequence shown is a composite derived from the analysis of 8 cDNA clones 20 derived from 3 libraries. The 5'-end of the sequence (nucleotides -60 to 351) is derived from a single cDNA clone but is also present in genomic DNA clones that have been isolated. Boxed region - typical haemopoietin receptor domain, amino acids 118-340.

Figure 2 is a photographic representation showing northern analysis of murine NR4 mRNA 25 expression in selected tissues and organs.

Figure 3 is a graphical representation depicting saturation isotherms of  $^{125}\text{I}$ -IL-13 and  $^{125}\text{I}$ -IL-4 binding; saturation isotherms depicted as Scatchard plots of IL-4 (•) and IL-13 (•) binding to (A) COS cells expressing the IL-13R $\alpha$  (NR4), (B) CTLL cells and (C) CTLL cells expressing 30 the IL-13R $\alpha$  (NR4). Data have been normalised to  $1 \times 10^4$  COS cells and  $1 \times 10^6$  CTLL cells and

binding was carried out on ice for 2 to 4 hours.

**Figure 4** is a graphical representation showing specificity of IL-4 and IL-13 binding; the ability of IL-4 (○) and IL-13 (●) to compete for  $^{125}\text{I}$ -IL-13 binding to (A) COS cells expressing the IL-13R $\alpha$  (NR4) and (C) CTLL cells expressing the IL-13R $\alpha$  (NR4) or to compete for  $^{125}\text{I}$ -IL-4 binding to (B) CTLL cells and (D) CTLL cells expressing the IL-13R $\alpha$  (NR4). Binding was carried out at 4°C for 2 to 4 hours and the data expressed as a percentage of the specific binding observed in the absence of a competitor (Δ).

10 **Figure 5** is a graphical representation showing factor dependent proliferation of cells expressing NR4. Two hundred (A) CTLL cells or (B) CTLL cells expressing the IL-13R $\alpha$  (NR4) were incubated in the absence of cytokine or with various concentrations of IL-2 (□), IL-4 (○) or IL-13 (●). After 48 hours viable cells were counted and data were expressed as a percentage of the number of viable cells observed with a maximal concentration of IL-2.

15

**Figure 6** is a photographic representation showing cross-species conservation of NR4 (IL-13R $\alpha$ ) gene.

20 **Figure 7** is a representation of the nucleotide and corresponding amino acid sequence of murine and human NR4 (IL-13R $\alpha$ ) genes. The nucleotide and predicted amino acid sequence of human (H) and murine (M) IL-13R $\alpha$  (NR4) were aligned by eye, with gaps (-) inserted to optimise the alignment. The numbering is for the murine clone, nucleotides that form part of the coding region are shown in upper case, whilst those of the untranslated regions are shown in lower case. Amino acids identical between the predicted murine and human proteins are 25 indicated by (\*). DNA encoding the murine signal sequence is underlined, with A26 or T27 being the predicted first amino acid of the mature protein.

**Figure 8** is a photographic representation showing  $^{125}\text{I}$ -IL-13 cross-linking to soluble NR4. Lane:  $^{125}\text{I}$ -IL-13 (100,000 cpm) + 2 $\mu\text{g}/\text{ml}$  soluble NR4; Lane 2:  $^{125}\text{I}$ -IL-13 (100,000 cpm) + 30 2 $\mu\text{g}/\text{ml}$  soluble NR4 in the presence of excess unlabelled IL-13; Lane 3:  $^{125}\text{I}$ -IL-13 (100,000

- 33 -

cpm) + 2 $\mu$ g/ml soluble NR4 in the presence of excess unlabelled IL-4.

**Figure 9** is a photographic representation of immunoprecipitation by anti-NR4 polyclonal antisera of cross-linked  $^{125}$ I-IL-13 with IL-13R $\alpha$  (NR4). Lanes 9-11: soluble IL-13R $\alpha$  (30  $\mu$ l of 3  $\mu$ g/ml) cross-linked to  $^{125}$ I-IL-13 (750,000 cpm) and immunoprecipitated with control rabbit serum, or with anti-NR4 polyclonal antiserum in the presence or absence of 100  $\mu$ g/ml FLAG peptide, respectively; Lanes 12-14: soluble IL-13R $\alpha$  (NR4) (30  $\mu$ l of 3  $\mu$ g/ml) cross-linked to  $^{125}$ I-IL-13 (750,000 cpm) in the presence of 0.5  $\mu$ g/ml unlabelled IL-13 and immunoprecipitated with an anti-IL-13R $\alpha$  (NR4) polyclonal antiserum also in the presence 10 or absence of 100  $\mu$ g/ml FLAG peptide, respectively.

**Figure 10** is a representation of the N-terminal amino acid sequence of murine NR4.

- 34 -

The following single and three letter abbreviations for amino acid residues are used in the specification:

5	Amino Acid	Three-letter	One-letter
		Abbreviation	Symbol
	Alanine	Ala	A
	Arginine	Arg	R
	Asparagine	Asn	N
10	Aspartic acid	Asp	D
	Cysteine	Cys	C
	Glutamine	Gln	Q
	Glutamic acid	Glu	E
	Glycine	Gly	G
15	Histidine	His	H
	Isoleucine	Ile	I
	Leucine	Leu	L
	Lysine	Lys	K
	Methionine	Met	M
20	Phenylalanine	Phe	F
	Proline	Pro	P
	Serine	Ser	S
	Threonine	Thr	T
	Tryptophan	Trp	W
25	Tyrosine	Tyr	Y
	Valine	Val	V
	Any residue	Xaa	X

**EXAMPLE 1****Isolation of genomic and cDNAs encoding NR4**

*Apol* digested genomic DNA, extracted from an embryonal stem cell line, was cloned into the  $\lambda$ ZAPII bacteriophage (Stratagene, LaJolla, CA). Approximately  $10^6$  plaques from this library

5 were screened with a  $^{32}$ P-labelled oligonucleotide corresponding to the sequence Trp-Ser-Asp-Trp-Ser (16). Positively hybridising clones were sequenced using an automated DNA sequencer according to the manufacturer's instructions (Applied Biosystems, Foster City, CA). One clone appeared to encode for part of a new member of the haemopoietin receptor family. Oligonucleotides were designed on the basis of this genomic DNA sequence and were used  
10 in the conventional manner to isolate clones from mouse peritoneal macrophage (Clontech Laboratories, Palo Alto, CA), mouse skin, mouse lung, mouse kidney, and WEHI-3B, (Stratagene, LaJolla, CA)  $\lambda$ -bacteriophage cDNA libraries.

**EXAMPLE 2****Construction of expression vectors and transfection of cells**

Using PCR, a derivative of the NR4 cDNA was generated which encoded for the IL-3 signal sequence [SEQ ID NO:5] and an N-terminal FLAG epitope-tag [SEQ ID NO:6] preceding the mature coding region of NR4 (Thr27 to Pro424; Figure 1). The PCR product was cloned into the mammalian expression vector pEF-BOS (17). Constructs were sequenced in their entirety  
20 prior to use. Cells were transfected and selected as previously described (16, 18).

**EXAMPLE 3****Northern blots**

Northern blots were performed as previously described (16). The source of hybridisation  
25 probes was as follows: NR4 - a PCR product from nucleotide 32 to 984 (Figure 1) and GAPDH - a cDNA fragment spanning nucleotides (19).

**EXAMPLE 4****Cytokines and experiments using radioiodinated cytokines**

IL-2, IL-4, IL-7, IL-9, IL-13 and IL-15 were obtained commercially (R & D Systems, Minneapolis MN). For radioiodination, cytokines were dissolved at a concentration of 100 5  $\mu$ g/ml in 10 mM sodium phosphate, 150 mM NaCl (PBS), 0.02% v/v Tween 20 and 0.02% w/v sodium azide at pH 7.4. An amount of 2 $\mu$ g of IL-13 was radioiodinated using the iodine monochloride method (20, 21), while 2 $\mu$ g of IL-4 was radiolabelled using di-iodo-Bolton-Hunter reagent (16). Binding studies and determination of the specific radioactivity and 10 bindability of labelled cytokines were performed as previously described (2).

10

For cross-linking experiments, recombinant murine IL-13 was produced as a FLAG-tagged protein in *Pichia pastoris*.

For cross-linking assays, aliquots of purified soluble IL-13R $\alpha$  (NR4) were incubated with  $^{125}$ I-15 IL-13 in the presence or absence of a competitor in a final volume of 20  $\mu$ l for at least 30 min at 40°C. Then 5  $\mu$ l of a 12 mM solution of BS $^3$  (Bis (Sulfosuccimidyl) suberate) in PBS containing 0.02% v/v Tween-20 was added and the mixtures were incubated for 30 min at 4°C. Samples were mixed with 8  $\mu$ l of 4XSDS sample buffer and analysed by 13% w/v SDS-PAGE under non-reducing conditions. Gels were dried and visualised by either 20 autoradiography or with a PhosphoImager.

**EXAMPLE 5****Proliferation Assays**

The proliferation of Ba/F3 and CTLL cells in response to cytokines was measured in Lux 60 25 microwell HL-A plates (Nunc Inc. IL, USA). Cells were washed three times in DMEM containing 20% v/v new born calf serum and resuspended at a concentration of  $2 \times 10^4$  cells per ml in the same medium. Aliquots of 10 $\mu$ l of the cell suspension were placed in the culture wells with 5 $\mu$ l of various concentrations of purified recombinant cytokines. After 2 days of 30 incubation at 37°C in a fully humidified incubator containing 10% v/v CO<sub>2</sub> in air, viable cells were counted using an inverted microscope.

**EXAMPLE 6****Cloning and Characterisation of Murine NR4**

A library was constructed in  $\lambda$ ZAP II using *ApoI* digested genomic DNA from embryonal stem cells and screened with a pool of  $^{32}$ P-labelled oligonucleotides encoding the amino acid sequence Trp-Ser-Asp-Trp-Ser found in many members of the haemopoietin receptor family. One hybridising bacteriophage clone was found to contain a sequence that appeared to encode part of a novel member of the haemopoietin receptor family. This receptor was given the operational name NR4. The sequence of the genomic clone was used to isolate cDNAs encoding NR4 from WEHI-3B cell, peritoneal macrophage, bone marrow, skin and kidney libraries. A composite of the nucleotide sequence [SEQ ID NO:1] and predicted amino acid sequence [SEQ ID NO:2] of these cDNAs is shown in Figure 1. The NR4 cDNA is predicted to encode for a protein of 424 amino acid residues, containing a putative signal sequence and transmembrane domain. The extracellular region of the protein contained an immunoglobulin-like domain (amino acids 27-117), in addition to a typical haemopoietin receptor domain (amino acids 118-340) which includes four conserved cysteine residues and the characteristic Trp-Ser-Asp-Trp-Ser motif (Figure 1; in bold as WSXWS). The cytoplasmic tail of the new receptor was 60 amino acids in length.

**EXAMPLE 7****Expression pattern of NR4 cDNA**

The pattern of NR4 mRNA expression was examined by Northern analyses. Two hybridising species of 5.2 and 2.2 kb in length were detected in mRNA from most tissues (Figure 2). NR4 mRNA was not detectable in skeletal muscle (Figure 2). Figure 8 shows expression of NR4 in mouse tissues.

**EXAMPLE 8****NR4 encodes the IL-13 receptor  $\alpha$ -chain (IL-13R $\alpha$ ) - a specific binding subunit of the IL-13 receptor**

The apparent molecular mass is from about 50,000 to about 70,000 daltons and more particularly about 55,000 to about 65,000 daltons for NR4 expressed in COS cells estimated from Western blots using an anti-FLAG antibody. This suggested that NR4 might encode the binding subunit of the IL-13 receptor in order to test this possibility, NR4 was expressed in COS cells. Untransfected COS cells expressed relatively low levels of IL-4 and IL-13 receptors. Upon transfection with a plasmid containing the NR4 cDNA, the number of IL-13 receptors but not IL-4 receptors expressed by COS cells was dramatically increased (Figure 3A; 100,000 to 500,000 receptors per cell). The affinity of IL-13 for NR4 expressed by COS cells was low ( $K_D$ ~2-10 nM) and binding was specific since it could compete with unlabelled IL-13 (Figure 4A) but not other cytokines including IL-2, IL-4, IL-7, IL-9 or IL-15. These results suggest that NR4 is the IL-13 receptor  $\alpha$ -chain (IL-13R $\alpha$ ).

15

**EXAMPLE 9****The IL-13R $\alpha$  (NR4) and the IL-4R $\alpha$  are shared components of the IL-4 and IL-13 receptors**

In order to investigate the relationship between IL-4 and IL-13 receptors, the IL-4 responsive cell line CTLL was examined. Parental CTLL cells expressed a single class of IL-4 receptor ( $K_D$ ~660 pM; ~3600 receptors per cell) but no detectable IL-13 receptors (Figure 3B). The IL-4 receptors expressed by CTLL cells appeared to be specific since binding of  $^{125}$ I-IL-4 could compete with unlabelled IL-4 but not IL-13 (Figure 4B). Upon expression of the IL-13R $\alpha$  (NR4) in CTLL cells no change was observed in the number or affinity of IL-4 receptors, while a single class of high affinity IL-13 receptors was detected (Figure 3C;  $K_D$ ~75 pM; 1350 receptors per cell). The affinity of IL-13 for the IL-13R $\alpha$  (NR4) expressed in CTLL cells was higher than in COS cells, suggesting that the former expressed a protein capable of interacting with the IL-13R $\alpha$  (NR4) to increase the affinity for IL-13. A likely candidate based on previous studies is the IL-4R $\alpha$ . In order to explore this possibility the ability of IL-4 to compete with  $^{125}$ I-IL-13 for binding to CTLL cells expressing the IL-13R $\alpha$

(NR4) was assessed. Figure 4B shows that IL-4 and IL-13 were equally effective in competing for  $^{125}\text{I}$ -IL-13 binding ( $\text{IC}_{50} \sim 300\text{pM}$ ; Figure 4C) and, in addition, were able to compete with  $^{125}\text{I}$ -IL-4 for binding ( $\text{IC}_{50} \sim 300\text{ pm}$ ; Figure 4D).

5

#### EXAMPLE 10

##### **Expression of the IL-13R $\alpha$ (NR4) is necessary for transduction of a proliferative signal by IL-13**

CTLL cells require the addition of exogenous cytokines for survival and proliferation. IL-2 was found to be a potent proliferative stimulus for CTLL cells ( $\text{EC}_{50} \sim 100\text{-}200\text{ pM}$ ), while

10 IL-4 was relatively weak ( $\text{EC}_{50} 2\text{-}7\text{ nM}$ ) and IL-13 was inactive (Figure 5A). Expression of the IL-13R $\alpha$  (NR4) in CTLL cells resulted in the ability to survive and proliferate weakly in response to IL-13 ( $\text{EC}_{50} \sim 700\text{ pM}$ ) and to proliferate somewhat more strongly than parental cells in response to IL-4 ( $\text{EC}_{50} \sim 700\text{ pM}$ ; Figure 5B).

15

#### EXAMPLE 11

##### **Cloning of Human IL-13R $\alpha$ (NR4)**

In order to determine whether genes homologous to murine IL-13R $\alpha$  (NR4) exist in other vertebrate species, a probe encompassing nucleotides 840 to 1270 of murine IL-13R $\alpha$  (NR4) was hybridised to *Eco*RI digested genomic DNA from various species. Hybridisation was 20 carried out in 500 mM  $\text{Na}_2\text{HPO}_4$  (~5xSSC) at 50°C overnight. The filter was washed in 40 mM  $\text{Na}_2\text{HPO}_4$  (~0.2xSSC) at 50°C for 2 hours and exposed to autoradiographic film for 48 hours. Figure 6 illustrates that relatively few (1 to 5) hybridising bands are observed in genomic DNA from various species, including human. This suggests that it is feasible to clone human IL-13R $\alpha$  (NR4) using a murine cDNA probe. A human bone marrow cDNA library 25 clones in the  $\lambda$ ZAPII bacteriophage was therefore screened with two probes (nucleotides 82-840 and 840 to 1270) from the murine IL-13R $\alpha$  (NR4) cDNA. Hybridisation was carried out overnight in 6xSSC, 0.1% w/v SDS at 42°C. Filters were washed at 2xSSC, 0.1% w/v SDS at 50°C for 2 hours and exposed for 48 hours to autoradiographic film. Plaques that hybridised to both murine IL-13R $\alpha$  (NR4) probes were picked and purified in the conventional 30 manner. The cDNA inserts from the hybridising bacteriophage were excised into the

pBluescript plasmid and sequenced in their entirety using an ABI automated sequencer. Figure 7 shows a composite of the sequence of the clones isolated and reveals that the clones encode a protein that shares a high degree of sequence similarity with murine IL-13R $\alpha$  (NR4). The clones encode the entire coding region of the protein. The high degree of sequence similarity (320/425 amino acids ~ 75%) predicates that this cDNA is the human homologue of the murine IL-13R $\alpha$  (NR4). The nucleotide sequence is represented as SEQ ID NO:3 and the amino acid sequence is SEQ ID NO:4.

#### EXAMPLE 12

##### 10 Soluble Murine IL-13R $\alpha$ (NR4) binds IL-13

Constructs were engineered to express soluble versions of NR4 with an N-terminal "FLAG" epitope (International Biotechnologies/Eastman Kodak, New Haven CT). First, a derivative of the mammalian expression vector pEF-BOS was generated so that it contained DNA encoding the signal sequence of murine IL-3 (MVLASSTTSIHTMLLLLLMLFHLGLQASIS

15 [SEQ ID NO:5]) and the FLAG epitope (DYKDDDDK [SEQ ID NO:6]), followed by a unique XbaI cloning site. This vector was named pEF/IL3SIG/FLAG. The mature extracellular part of the NR4 coding region (Thr27 to Thr344) was generated by PCR using primers 1478 and 1480. The resulting product was digested with XbaI and was cloned into the XbaI site of pEF/IL3SIG/FLAG to give pEF/IL3SIG/FLAG/sol NR4. The identity of the  
20 construct was confirmed by dideoxy sequencing.

OLIGO 1478 5' AGCTTCTAGAACAGAAGTTCAGGCCACCTGTG 3' [SEQ ID NO:7];  
OLIGO 1480 5' AACTCCACCTTCTACACCACCTGATCTAGA 3' [SEQ ID NO:8].

25 After transfection into CHO cells, expressed, soluble NR4 was purified from CHO cell-conditioned medium on an anti-FLAG antibody (M2) affinity column by elution with free FLAG peptide (Science Imaging Systems).

30 Consistent with the low affinity of IL-13 for NR4 expressed by COS cells, purified soluble NR4 appeared unable to bind IL-13 as assessed by gel filtration chromatography. However, using sensitive cross-linking assays, the ability of soluble IL-13R $\alpha$  (NR4) to bind IL-13 was

- 41 -

demonstrated (Figure 8, lane 1). This interaction was competed for by unlabelled IL-13 but not by unlabelled IL-4 (Figure 8, lanes 2 and 3).

### EXAMPLE 13

#### A Polyclonal Antisera to Soluble IL-13R $\alpha$ (NR4)

A polyclonal antiserum to NR4 was prepared by injecting purified soluble NR4 into rabbits which were bled after 3 months. This antisera immunoprecipitated the cross-linked product of  $^{125}\text{I}$ -IL-13 with soluble NR4 (Figure 9, lane 11) while no immunoprecipitation was observed with pre-immune serum (Figure 9, lane 9). Immunoprecipitation of the complex was not inhibited by the FLAG peptide (Figure 9, lane 10).

The immunoprecipitation assay was conducted as follows:

The cross-linking reactions were terminated by the addition of Tris-HCl, pH 7.5, to a final concentration of 40 mM. The samples were then mixed with 1:50 diluted control rabbit serum or anti-NR4 serum which had been pre-incubated with or without FLAG peptide. After incubation for 30 min at 4°C, the mixtures were added to 40  $\mu\text{l}$  of 50% v/v protein G-Sepharose gel slurry (Pharmacia) and incubated for 30 min at 4°C. The samples were centrifuged and the protein G beads were washed 3 x 0.5 ml PBS, mixed with 40  $\mu\text{l}$  of 2X concentrated SDS-PAGE sample buffer and heated for 2 min at 95°C. The supernatants were analysed by 13% w/v SDS-PAGE under non-reducing conditions.

### EXAMPLE 14

#### N-terminal Amino Acid Sequence of NR4

The N-terminal amino acid sequence of NR4 was determined and is shown in Figure 10.

**EXAMPLE 15****Assay for IL-13**

IL-13 is a cytokine that is implicated in the production of IgE, the immunoglobulin isotype important in allergic diseases such as asthma. Monitoring IL-13 levels may, therefore, be 5 an important diagnostic. Since IL-4 and IL-13 share many biological effects, generating an assay that discriminates these cytokines is also important.

NR4 expressed in COS cells binds  $^{125}\text{I}$ -IL-13. This binding is inhibited in a dose dependent manner by unlabelled IL-13, in the presence of a large amount of irrelevant protein such as 10 calf serum or human serum. IL-4 shows no ability to compete for  $^{125}\text{I}$ -IL-13 binding in this situation and, therefore, this assay appears to be specific for IL-13.

The assay is set up by coating soluble NR4 on ELISA plates and using, for example, 15 fluorescent labelled IL-13 as the probe. The presence of unlabelled IL-13 in a test sample then registers as a decrease in the fluorescent signal.

Similar assays are set up that measure both IL-4 and IL-13 by using cells that express NR4 and IL-4 receptor  $\alpha$ -chain. These include CTLL cells which normally express IL-4 receptor  $\alpha$ -chain and which are engineered to express NR4. Binding of  $^{125}\text{I}$ -IL-13 or  $^{125}\text{I}$ -IL-4 can 20 be inhibited by unlabelled forms of both IL-4 and IL-13.

**EXAMPLE 16****Modifications to IL-4 and IL-13**

Mutations are introduced into regions of the molecules that are predicated to be functionally 25 important. In the case of NR4, this includes the region that interacts with IL-13, the region which interacts with IL-4 receptor  $\alpha$ -chain or the region that interacts with IL-4 when this cytokine is bound to the IL-4 receptor  $\alpha$ -chain. These regions are determined by direct experiment, for example, by solving the structure of NR4 or complexes of NR4 with other

proteins like IL-4, IL-13 and the IL-4 receptor  $\alpha$ -chain or by modeling these proteins on similar proteins for which structural information exists, for example, the growth hormone/growth hormone receptor complex. Resulting NR4 mutants are then individually tested for improved function.

5

In an alternative method, random mutations are generated in the molecules. Suitable techniques include synthesis of NR4 cDNA using a polymerase and reaction conditions that promote incorporation of the incorrect dNTP and use of a technique called DNA shuffling (23, 24, 25, 26).

10

After generating random mutants of the cDNA of interest, potentially useful mutants are selected. In the case of NR4, an assay is based on knowledge that if NR4 is expressed in cells which lack IL-4 receptor  $\alpha$ -chain (e.g. COS cells), then cells are obtained that cannot bind IL-4 with any detectable affinity and binds IL-13 with low affinity. Thus, if COS cells 15 are transfected with Nr4 and allowed to bind FITC-conjugated IL-4 and phycoerythrin-conjugated IL-13, the unbound ligand washed away, the no IL-4 will bind and any IL-13 that had bound would dissociate during the washing.

If these cells are FACS-sorted, then little or no signal in either the FITC or PE channel 20 would be obtained. COS cells are transfected with  $10^6$  to  $10^7$  random mutants of NR4 and processed for binding. Any cells sorted which bind the cytokines better than those transfected with wild type NR4 can be FACS sorted. The plasmids containing these "improved" NR4 cDNAs may be recovered, expanded in *E. coli* and used again in COS 25 cells to confirm the improvement. Any mutants that are consistently better can then be used for the introduction of further random changes into an order to get even better molecules. This iterative process may be repeated several times.

Those skilled in the art will appreciate that the invention described herein is susceptible to 30 variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes

all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

卷之三

## BIBLIOGRAPHY

1. Du, X.X. and Williams, D.A. (1994) *Blood* 83: 2023-2030.
2. Yang, Y.C. and Yin, T. (1992) *Biofactors* 4: 15-21.
3. Paul, S.R., Bennett, F., Calvetti, J.A., Kelleher, K., Wood, C.R., O'Hara, R.J.J., Leary, A.C., Sibley, B., Clark, S.C., Williams, D.A. and Yang, Y.-C. (1990) *Proc. Natl. Acad. Sci. USA* 87: 7512.
4. Musashi, M., Clark, S.C., Sudo, T., Urdal, D.L., and Ogawa, M. (1991) *Blood* 78: 1448-1451.
5. Schibler, K.R., Yang, Y.C. and Christensen, R.D. (1992) *Blood* 80: 900-3.
6. Tsuji, K., Lyman, S.D., Sudo, T., Clark, S.C., and Ogawa, M. (1992) *Blood* 79: 2855-60.
7. Burstein, S.A., Mei, R.L., Henthorn, J., Friese, P. and turner, K. (1992) *J. Cell. Physiol.* 153: 305-12.
8. Hangoc, G., Yin, T., Cooper, S., Schendel, P., Yang, Y.C. and Broxmeyer, H.E. (1993) *Blood* 81: 965-72.
9. Teramura, M., Kobayashi, S., Hoshino, S., Oshimi, K. and Mizoguchi, H. (1992) *Blood* 79: 327-31.
10. Yonemura, Y., Kawakita, M., Masuda, T., Fujimoto, K., Kato, K. and Takatsuki, K. (1992) *Exp. Hematol.* 20: 1011-6.
11. Baumann, H. and Schendel, P. (1991) *J. Biol. Chem.* 266: 20424-7.
12. Kawashima, I., Ohsumi, J., Mita-Honjo, K., Shimoda-Takano, K., Ishikawa, H., Sakakibara, S., Miyadai, K. and Takiguchi, Y. (1991) *Febs. Lett.* 283: 199-202.
13. Keller, D.C., Du, X.X., Srour, E.f., Hoffman, R. and Williams, D.A. (1993) *Blood* 82: 1428-35.
14. McKenzie, A.N.J. and Zurawski, G. (1994) *Guidebood to cytokines and their receptors*, Oxford University Press. Oxford.
15. Zurawski, G. and de Vries, J.E. (1994) *Immunol. Today* 15: 19-26.

16. Hilton, D.J., Hilton, A.A., Raicevic, A., Rakar, S., Harrison-Smith, M., Gough, N.M., Begley, C.G., Metcalf, D., Nicola, N.A. and Wilson, T.A. (1994) *EMBO J.* 13: 4765-4775.
17. Mizushima, S. and Nagata, S. (1990) *Nucleic Acids Res.* 18: 5322.
18. Lock, P., Metcalf, D. and Nicola, N.A. (1994) *Proc. Natl. Acad. Sci. USA* 91: 252-256.
19. Dugaiczyk, A. *et al* (1983) *Biochemistry* 22: 1605-1613.
20. Contreras, M.A., Bale, W.F. and Spar, I.L. (1983) *Methods in Enzymol.* 92: 277-292.
21. Hilton, D.J. and Nicola, N.A. (1992) *J. Biol. Chem.* 267: 10238-10247.
22. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular cloning: A Laboratory Manual* Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
23. Stemmer, W.P.C., (1994) *Nature* 370: 389-391.
24. Stemmer, W.P.C., (1995) *Biotechnology* 13: 549-553.
25. Gassmann *et al* (1995) *Proc. Natl. Acad. Sci. USA* 92: 1292-1296.
26. Grameri *et al* (1996) *Nature Biotechnology* 14: 315-319.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: (Countries other than US) AMRAD OPERATIONS PTY LTD  
(US only) WILLSON, T; NICOLA, NA; HILTON, DJ;  
METCALF, D ZAN, JG

(ii) TITLE OF INVENTION: A NOVEL HAEMOPOIETIN RECEPTOR AND  
GENETIC SEQUENCES ENCODING SAME

(iii) NUMBER OF SEQUENCES: 8

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: DAVIES COLLISON CAVE  
(B) STREET: 1 LITTLE COLLINS STREET  
(C) CITY: MELBOURNE  
(D) STATE: VICTORIA  
(E) COUNTRY: AUSTRALIA  
(F) ZIP: 3000

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT INTERNATIONAL  
(B) FILING DATE: 23-OCT-1996

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: PN6135/95  
(B) FILING DATE: 23-OCT-1995  
(A) APPLICATION NUMBER: PN7276/95  
(B) FILING DATE: 22-DEC-1995  
(A) APPLICATION NUMBER: PO2208/96  
(B) FILING DATE: 09-SEP-1996

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: HUGHES DR, E JOHN L  
(C) REFERENCE/DOCKET NUMBER: EJH/EK

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: +61 3 9254 2777  
(B) TELEFAX: +61 3 9254 2770

- 48 -

## (1) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1323 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: ..1278
- (C) X, unknown nucleotide;
- Xaa, unknown amino acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TGAAAAGATA GAATAATGG CCTCGTGCCG AATTCGGCAC GAGCCGAGGC GAGGGCCCTGC	-1
ATG GCG CGG CCA GCG CTG CTG GGC GAG CTG TTG GTG CTG CTA CTG TGG	48
Met Ala Arg Pro Ala Leu Leu Gly Glu Leu Leu Val Leu Leu Leu Trp	
1 5 10 15	
ACC GCC ACC GTG XXX GGC CAA GTT GCC GCG GCC ACA GAA GTT CAG CCA	96
Thr Ala Thr Val Xaa Gly Gln Val Ala Ala Ala Thr Glu Val Gln Pro	
20 25 30	
CCT GTG ACG AAT TTG AGC GTC TCT GTC GAA AAT CTC TGC ACG ATA ATA	144
Pro Val Thr Asn Leu Ser Val Glu Asn Leu Cys Thr Ile Ile	
35 40 45	
TGG ACG TGG AGT CCT CCT GAA GGA GCC AGT CCA AAT TGC ACT CTC AGA	192
Trp Thr Trp Ser Pro Pro Glu Gly Ala Ser Pro Asn Cys Thr Leu Arg	
50 55 60	
TAT TTT AGT CAC TTT GAT GAC CAA CAG GAT AAG AAA ATT GCT CCA GAA	240
Tyr Phe Ser His Phe Asp Asp Gln Gln Asp Lys Lys Ile Ala Pro Glu	
65 70 75 80	
ACT CAT CGT AAA GAG GAA TTA CCC CTG GAT GAG AAA ATC TGT CTG CAG	288
Thr His Arg Lys Glu Leu Pro Leu Asp Glu Lys Ile Cys Leu Gln	
85 90 95	
GTG GGC TCT CAG TGT AGT GCC AAT GAA AGT GAG AAG CCT AGC CCT TTG	336
Val Gly Ser Gln Cys Ser Ala Asn Glu Ser Glu Lys Pro Ser Pro Leu	
100 105 110	
GTG AAA AAG TGC ATC TCA CCC CCT GAA GGT GAT CCT GAG TCC GCT GTG	384
Val Lys Lys Cys Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala Val	
115 120 125	

- 49 -

ACT GAG CTC AAG TGC ATT TGG CAT AAC CTG AGC TAT ATG AAG TGT TCC	432
Thr Glu Leu Lys Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser	
130 135 140	
TGG CTC CCT GGA AGG AAT ACA AGC CCT GAC ACA CAC TAT ACT CTG TAC	480
Trp Leu Pro Gly Arg Asn Thr Ser Pro Asp Thr His Tyr Thr Leu Tyr	
145 150 155 160	
TAT TGG TAC AGC AGC CTG GAG AAA AGT CGT CAA TGT GAA AAC ATC TAT	528
Tyr Trp Tyr Ser Ser Leu Glu Lys Ser Arg Gln Cys Glu Asn Ile Tyr	
165 170 175	
AGA GAA GGT CAA CAC ATT GCT TGT TCC TTT AAA TTG ACT AAA GTG GAA;	576
Arg Glu Gly Gln His Ile Ala Cys Ser Phe Lys Leu Thr Lys Val Glu	
1 180 185 190	
CCT XXX AGT TTT GAA CAT CAG AAC GTT CAA ATA ATG GTC AAG GAT AAT	624
Pro Xaa Ser Phe Glu His Gln Asn Val Gln Ile Met Val Lys Asp Asn	
195 200 205	
GCT GGG AAA ATT AGG CCA TCC TGC AAA ATA GTG TCT TTA ACT TCC TAT	672
Ala Gly Lys Ile Arg Pro Ser Cys Lys Ile Val Ser Leu Thr Ser Tyr	
210 215 220	
GTG AAA CCT GAT CCT CCA CAT ATT AAA CAT CTT CTC CTC AAA AAT GGT	720
Val Lys Pro Asp Pro Pro His Ile Lys His Leu Leu Lys Asn Gly	
225 230 235 240	
GCC TTA TTA GTG CAG TGG AAG AAT CCA CAA ATT TTT AGA AGC AGA TGC	768
Ala Leu Leu Val Gln Trp Lys Asn Pro Gln Asn Phe Arg Ser Arg Cys	
245 250 255	
TTA ACT TAT GAA GTG GAG GTC AAT AAT ACT CAA ACC GAC CGA CAT AAT	816
Leu Thr Tyr Glu Val Glu Val Asn Asn Thr Gln Thr Asp Arg His Asn	
260 265 270	
ATT TTA GAG GTT GAA GAG GAC AAA TGC CAG AAT TCC GAA TCT GAT AGA	864
Ile Leu Glu Val Glu Glu Asp Lys Cys Gln Asn Ser Glu Ser Asp Arg	
275 280 285	
AAC ATG GAG GGT ACA AGT TGT TTC CAA CTC CCT GGT GTT CTT GCC GAC	912
Asn Met Glu Gly Thr Ser Cys Phe Gln Leu Pro Gly Val Leu Ala Asp	
290 295 300	
GCT GTC TAC ACA GTC AGA GTA AGA GTC AAA ACA AAC AAG TTA TGC TTT	960
Ala Val Tyr Thr Val Arg Val Arg Val Lys Thr Asn Lys Leu Cys Phe	
305 310 315 320	
GAT GAC AAC AAA CTG TGG AGT GAT TGG AGT GAA GCA CAG AGT ATA GGT	1008
Asp Asp Asn Lys Leu Trp Ser Asp Trp Ser Glu Ala Gln Ser Ile Gly	
325 330 335	
AAG GAG CAA AAC TCC ACC TTC TAC ACC ACC ATG TTA CTC ACC ATT CCA	1056
Lys Glu Gln Asn Ser Thr Phe Tyr Thr Thr Met Leu Leu Thr Ile Pro	
340 345 350	

- 50 -

GTC TTT GTC GCA GTG GCA GTC ATA ATC CTC CTT TTT TAC CTG AAA AGG	1104																																			
Val Phe Val Ala Val Ala Val Ile Ile Leu Leu Phe Tyr Leu Lys Arg																																				
355	360	365		CTT AAG ATC ATT ATA TTT CCT CCA ATT CCT GAT CCT GGC AAG ATT TTT	1152	Leu Lys Ile Ile Ile Phe Pro Pro Ile Pro Asp Pro Gly Lys Ile Phe		370	375	380		AAA GAA ATG TTT GGA GAC CAG AAT GAT GAT ACC CTG CAC TGG AAG AAG	1200	Lys Glu Met Phe Gly Asp Gln Asn Asp Asp Thr Leu His Trp Lys Lys		385	390	395	400	TAT GAC ATC TAT GAG AAA CAA TCC AAA GAA GAA ACG GAT TCT GTA GTG	1248	Tyr Asp Ile Tyr Glu Lys Gln Ser Lys Glu Glu Thr Asp Ser Val Val		405	410	415		CTG ATA GAA AAC CTG AAG AAA GCA GCT CCT TGATGGGGAG AAGTGATTTC	1298	Leu Ile Glu Asn Leu Lys Lys Ala Ala Pro		420	425		TTTCTTGCCT TCAATGTGAC CCTGT	1323
365																																				
CTT AAG ATC ATT ATA TTT CCT CCA ATT CCT GAT CCT GGC AAG ATT TTT	1152																																			
Leu Lys Ile Ile Ile Phe Pro Pro Ile Pro Asp Pro Gly Lys Ile Phe																																				
370	375	380		AAA GAA ATG TTT GGA GAC CAG AAT GAT GAT ACC CTG CAC TGG AAG AAG	1200	Lys Glu Met Phe Gly Asp Gln Asn Asp Asp Thr Leu His Trp Lys Lys		385	390	395	400	TAT GAC ATC TAT GAG AAA CAA TCC AAA GAA GAA ACG GAT TCT GTA GTG	1248	Tyr Asp Ile Tyr Glu Lys Gln Ser Lys Glu Glu Thr Asp Ser Val Val		405	410	415		CTG ATA GAA AAC CTG AAG AAA GCA GCT CCT TGATGGGGAG AAGTGATTTC	1298	Leu Ile Glu Asn Leu Lys Lys Ala Ala Pro		420	425		TTTCTTGCCT TCAATGTGAC CCTGT	1323								
380																																				
AAA GAA ATG TTT GGA GAC CAG AAT GAT GAT ACC CTG CAC TGG AAG AAG	1200																																			
Lys Glu Met Phe Gly Asp Gln Asn Asp Asp Thr Leu His Trp Lys Lys																																				
385	390	395	400	TAT GAC ATC TAT GAG AAA CAA TCC AAA GAA GAA ACG GAT TCT GTA GTG	1248	Tyr Asp Ile Tyr Glu Lys Gln Ser Lys Glu Glu Thr Asp Ser Val Val		405	410	415		CTG ATA GAA AAC CTG AAG AAA GCA GCT CCT TGATGGGGAG AAGTGATTTC	1298	Leu Ile Glu Asn Leu Lys Lys Ala Ala Pro		420	425		TTTCTTGCCT TCAATGTGAC CCTGT	1323																
395	400																																			
TAT GAC ATC TAT GAG AAA CAA TCC AAA GAA GAA ACG GAT TCT GTA GTG	1248																																			
Tyr Asp Ile Tyr Glu Lys Gln Ser Lys Glu Glu Thr Asp Ser Val Val																																				
405	410	415		CTG ATA GAA AAC CTG AAG AAA GCA GCT CCT TGATGGGGAG AAGTGATTTC	1298	Leu Ile Glu Asn Leu Lys Lys Ala Ala Pro		420	425		TTTCTTGCCT TCAATGTGAC CCTGT	1323																								
415																																				
CTG ATA GAA AAC CTG AAG AAA GCA GCT CCT TGATGGGGAG AAGTGATTTC	1298																																			
Leu Ile Glu Asn Leu Lys Lys Ala Ala Pro																																				
420	425																																			
TTTCTTGCCT TCAATGTGAC CCTGT	1323																																			

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 426 amino acids
  - (B) TYPE: amino acid
  - (C) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Arg Pro Ala Leu Leu Gly Glu Leu Leu Val Leu Leu Leu Trp																																	
1	5	10	15	Thr Ala Thr Val Xaa Gly Gln Val Ala Ala Ala Thr Glu Val Gln Pro		20	25	30		Pro Val Thr Asn Leu Ser Val Ser Val Glu Asn Leu Cys Thr Ile Ile		35	40	45		Trp Thr Trp Ser Pro Pro Glu Gly Ala Ser Pro Asn Cys Thr Leu Arg		50	55	60		Tyr Phe Ser His Phe Asp Asp Gln Gln Asp Lys Lys Ile Ala Pro Glu		65	70	75	80	Thr His Arg Lys Glu Glu Leu Pro Leu Asp Glu Lys Ile Cys Leu Gln		85	90	95	
10	15																																
Thr Ala Thr Val Xaa Gly Gln Val Ala Ala Ala Thr Glu Val Gln Pro																																	
20	25	30		Pro Val Thr Asn Leu Ser Val Ser Val Glu Asn Leu Cys Thr Ile Ile		35	40	45		Trp Thr Trp Ser Pro Pro Glu Gly Ala Ser Pro Asn Cys Thr Leu Arg		50	55	60		Tyr Phe Ser His Phe Asp Asp Gln Gln Asp Lys Lys Ile Ala Pro Glu		65	70	75	80	Thr His Arg Lys Glu Glu Leu Pro Leu Asp Glu Lys Ile Cys Leu Gln		85	90	95							
30																																	
Pro Val Thr Asn Leu Ser Val Ser Val Glu Asn Leu Cys Thr Ile Ile																																	
35	40	45		Trp Thr Trp Ser Pro Pro Glu Gly Ala Ser Pro Asn Cys Thr Leu Arg		50	55	60		Tyr Phe Ser His Phe Asp Asp Gln Gln Asp Lys Lys Ile Ala Pro Glu		65	70	75	80	Thr His Arg Lys Glu Glu Leu Pro Leu Asp Glu Lys Ile Cys Leu Gln		85	90	95													
45																																	
Trp Thr Trp Ser Pro Pro Glu Gly Ala Ser Pro Asn Cys Thr Leu Arg																																	
50	55	60		Tyr Phe Ser His Phe Asp Asp Gln Gln Asp Lys Lys Ile Ala Pro Glu		65	70	75	80	Thr His Arg Lys Glu Glu Leu Pro Leu Asp Glu Lys Ile Cys Leu Gln		85	90	95																			
60																																	
Tyr Phe Ser His Phe Asp Asp Gln Gln Asp Lys Lys Ile Ala Pro Glu																																	
65	70	75	80	Thr His Arg Lys Glu Glu Leu Pro Leu Asp Glu Lys Ile Cys Leu Gln		85	90	95																									
75	80																																
Thr His Arg Lys Glu Glu Leu Pro Leu Asp Glu Lys Ile Cys Leu Gln																																	
85	90	95																															
95																																	

- 51 -

Val Gly Ser Gln Cys Ser Ala Asn Glu Ser Glu Lys Pro Ser Pro Leu  
 100 105 110

Val Lys Lys Cys Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala Val  
 115 120 125

Thr Glu Leu Lys Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser  
 130 135 140

Trp Leu Pro Gly Arg Asn Thr Ser Pro Asp Thr His Tyr Thr Leu Tyr  
 145 150 155 160

Tyr Trp Tyr Ser Ser Leu Glu Lys Ser Arg Gln Cys Glu Asn Ile Tyr  
 165 170 175 |

Arg Glu Gly Gln His Ile Ala Cys Ser Phe Lys Leu Thr Lys Val Glu  
 180 185 190

Pro Xaa Ser Phe Glu His Gln Asn Val Gln Ile Met Val Lys Asp Asn  
 195 200 205

Ala Gly Lys Ile Arg Pro Ser Cys Lys Ile Val Ser Leu Thr Ser Tyr  
 210 215 220

Val Lys Pro Asp Pro Pro His Ile Lys His Leu Leu Leu Lys Asn Gly  
 225 230 235 240

Ala Leu Leu Val Gln Trp Lys Asn Pro Gln Asn Phe Arg Ser Arg Cys  
 245 250 255

Leu Thr Tyr Glu Val Glu Val Asn Asn Thr Gln Thr Asp Arg His Asn  
 260 265 270

Ile Leu Glu Val Glu Glu Asp Lys Cys Gln Asn Ser Glu Ser Asp Arg  
 275 280 285

Asn Met Glu Gly Thr Ser Cys Phe Gln Leu Pro Gly Val Leu Ala Asp  
 290 295 300

Ala Val Tyr Thr Val Arg Val Arg Val Lys Thr Asn Lys Leu Cys Phe  
 305 310 315 320

Asp Asp Asn Lys Leu Trp Ser Asp Trp Ser Glu Ala Gln Ser Ile Gly  
 325 330 335

Lys Glu Gln Asn Ser Thr Phe Tyr Thr Thr Met Leu Leu Thr Ile Pro  
 340 345 350

Val Phe Val Ala Val Ala Val Ile Ile Leu Leu Phe Tyr Leu Lys Arg  
 355 360 365

Leu Lys Ile Ile Ile Phe Pro Pro Ile Pro Asp Pro Gly Lys Ile Phe  
 370 375 380

- 52 -

Lys Glu Met Phe Gly Asp Gln Asn Asp Asp Thr Leu His Trp Lys Lys  
 385 390 395 400

Tyr Asp Ile Tyr Glu Lys Gln Ser Lys Glu Glu Thr Asp Ser Val Val  
 405 410 415

Leu Ile Glu Asn Leu Lys Lys Ala Ala Pro  
 420 425

## (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1323 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 1..1278

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GAGTCTAACAA CGGACCAAGG AGTTAACAC GTGCGGCCGG GTTCCGAGGC GAGAGGCTGC

ATG GAG TGG CGG GCG CGG CTC TGC GGG CTG TGG GCG CTG CTG CTC TGC  
 Met Glu Trp Pro Ala Arg Leu Cys Gly Leu Trp Ala Leu Leu Leu Cys  
 1 5 10 15

GCC GGC GGC GGG GGC GGG GGC GCG CCT ACG GAA ACT CAG CCA  
 Ala Gly Gly Gly Gly Gly Gly Gly Ala Pro Thr Glu Thr Gln Pro  
 20 25 30

CCT GTG ACA AAT TTG AGT GTC TCT GTT GAA AAC CTC TGC ACA GTA ATA  
 Pro Val Thr Asn Leu Ser Val Ser Val Glu Asn Leu Cys Thr Val Ile  
 35 40 45

TGG ACA TGG AAT CCA CCC GAG GGA GCC AGC TCA AAT TGT AGT CTA TGG  
 Trp Thr Trp Asn Pro Pro Glu Gly Ala Ser Ser Asn Cys Ser Leu Trp  
 50 55 60

TAT TTT AGT CAT TTT GGC GAC AAA CAA GAT AAG AAA ATA GCT CCG GAA  
 Tyr Phe Ser His Phe Gly Asp Lys Gln Asp Lys Lys Ile Ala Pro Glu  
 65 70 75 80

ACT CGT CGT TCA ATA GAA GTA CCC CTG AAT GAG AGG ATT TGT CTG CAA  
 Thr Arg Arg Ser Ile Glu Val Pro Leu Asn Glu Arg Ile Cys Leu Gln  
 85 90 95

- 53 -

GTG GGG TCC CAG TGT AGC ACC AAT GAG AGT GAG AAG CCT AGC ATT TTG Val Gly Ser Gln Cys Ser Thr Asn Glu Ser Glu Lys Pro Ser Ile Leu 100 105 110	336
GTT GAA AAA TGC ATC TCA CCC CCA GAA GGT GAT CCT GAG TCT GCT GTG Val Glu Lys Cys Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala Val 115 120 125	384
ACT GAA CTT CAA TGC ATT TGG CAC AAC CTG AGC TAC ATG AAG TGT TCT Thr Glu Leu Gln Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser 130 135 140	432
TGG CTC CCT GGA AGG AAT ACC AGT CCC GAC ACT AAC TAT ACT CTC TAC Trp Leu Pro Gly Arg Asn Thr Ser Pro Asp Thr Asn Tyr Thr Leu Tyr 145 150 155 160	480
TAT TGG CAC AGA AGC CTG GAA AAA ATT CAT CAA TGT GAA AAC ATC TTT Tyr Trp His Arg Ser Leu Glu Lys Ile His Gln Cys Glu Asn Ile Phe 165 170 175	528
AGA GAA GGC CAA TAC TTT GGT TGT TCC TTT GAT CTG ACC AAA GTG AAG Arg Glu Gly Gln Tyr Phe Gly Cys Ser Phe Asp Leu Thr Lys Val Lys 180 185 190	576
GAT TCC AGT TTT GAA CAA CAC AGT GTC CAA ATA ATG GTC AAG GAT AAT Asp Ser Ser Phe Glu Gln His Ser Val Gln Ile Met Val Lys Asp Asn 195 200 205	624
GCA GGA AAA ATT AAA CCA TCC TTC AAT ATA GTG CCT TTA ACT TCC CGT Ala Gly Lys Ile Lys Pro Ser Phe Asn Ile Val Pro Leu Thr Ser Arg 210 215 220	672
GTG AAA CCT GAT CCT CCA CAT ATT AAA AAC CTC TCC TTC CAC AAT GAT Val Lys Pro Asp Pro Pro His Ile Lys Asn Leu Ser Phe His Asn Asp 225 230 235 240	720
GAC CTA TAT GTG CAA TGG GAG AAT CCA CAG AAT TTT ATT AGC AGA TGC Asp Leu Tyr Val Gln Trp Glu Asn Pro Gln Asn Phe Ile Ser Arg Cys 245 250 255	768
CTA TTT TAT GAA GTA GAA GTC AAT AAC AGC CAA ACT GAG ACA CAT AAT Leu Phe Tyr Glu Val Glu Val Asn Asn Ser Gln Thr Glu Thr His Asn 260 265 270	816
GTT TTC TAC GTC CAA GAG GCT AAA TGT GAG AAT CCA GAA TTT GAG AGA Val Phe Tyr Val Gln Glu Ala Lys Cys Glu Asn Pro Glu Phe Glu Arg 275 280 285	864
AAT GTG GAG AAT ACA TCT TGT TTC ATG GTC CCT GGT GTT CTT CCT GAT Asn Val Glu Asn Thr Ser Cys Phe Met Val Pro Gly Val Leu Pro Asp 290 295 300	912
ACT TTG AAC ACA GTC AGA ATA AGA GTC AAA ACA AAT AAG TTA TGC TAT Thr Leu Asn Thr Val Arg Ile Arg Val Lys Thr Asn Lys Leu Cys Tyr 305 310 315 320	960

- 54 -

GAG GAT GAC AAA CTC TGG AGT AAT TGG AGC CAA GAA ATG AGT ATA GGT	1008		
Glu Asp Asp Lys Leu Trp Ser Asn Trp Ser Gln Glu Met Ser Ile Gly			
325	330	335	
AAG AAG CGC AAT TCC ACA CTC TAC ATA ACC ATG TTA CTC ATT GTT CCA	1056		
Lys Lys Arg Asn Ser Thr Leu Tyr Ile Thr Met Leu Leu Ile Val Pro			
340	345	350	
GTC ATC GTC GCA GGT GCA ATC ATA GTA CTC CTG CTT TAC CTA AAA AGG	1104		
Val Ile Val Ala Gly Ala Ile Ile Val Leu Leu Tyr Leu Lys Arg			
355	360	365	
CTC AAG ATT ATT ATA TTC CCT CCA ATT CCT GAT CCT GGC AAG ATT TTT	1152		
Leu Lys Ile Ile Ile Phe Pro Pro Ile Pro Asp Pro Gly Lys Ile Phe			
370	375	380	
AAA GAA ATG TTT GGA GAC CAG AAT GAT GAT ACT CTG CAC TGG AAG AAG	1200		
Lys Glu Met Phe Gly Asp Gln Asn Asp Asp Thr Leu His Trp Lys Lys			
385	390	395	400
TAC GAC ATC TAT GAG AAG CAA ACC AAG GAG GAA ACC GAC TCT GTA GTG	1248		
Tyr Asp Ile Tyr Glu Lys Gln Thr Lys Glu Glu Thr Asp Ser Val Val			
405	410	415	
CTG ATA GAA AAC CTG AAG AAA GCC TCT CAG TGATGGAGAT AATTTATTT	1298		
Leu Ile Glu Asn Leu Lys Lys Ala Ser Gln			
420	425		
TACCTTCACT GTGACCTTGA GAAGA	1323		

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 426 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Glu Trp Pro Ala Arg Leu Cys Gly Leu Trp Ala Leu Leu Leu Cys			
1	5	10	15
Ala Gly Gly Gly Gly Gly Gly Ala Pro Thr Glu Thr Gln Pro			
20	25	30	
Pro Val Thr Asn Leu Ser Val Ser Val Glu Asn Leu Cys Thr Val Ile			
35	40	45	
Trp Thr Trp Asn Pro Pro Glu Gly Ala Ser Ser Asn Cys Ser Leu Trp			
50	55	60	

- 55 -

Tyr Phe Ser His Phe Gly Asp Lys Gln Asp Lys Lys Ile Ala Pro Glu  
 65 70 75 80

Thr Arg Arg Ser Ile Glu Val Pro Leu Asn Glu Arg Ile Cys Leu Gln  
 85 90 95

Val Gly Ser Gln Cys Ser Thr Asn Glu Ser Glu Lys Pro Ser Ile Leu  
 100 105 110

Val Glu Lys Cys Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala Val  
 115 120 125

Thr Glu Leu Gln Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser  
 130 135 140

Trp Ile Pro Gly Arg Asn Thr Ser Pro Asp Thr Asn Tyr Thr Leu Tyr  
 145 150 155 160

Tyr Trp His Arg Ser Leu Glu Lys Ile His Gln Cys Glu Asn Ile Phe  
 165 170 175

Arg Glu Gly Gln Tyr Phe Gly Cys Ser Phe Asp Leu Thr Lys Val Lys  
 180 185 190

Asp Ser Ser Phe Glu Gln His Ser Val Gln Ile Met Val Lys Asp Asn  
 195 200 205

Ala Gly Lys Ile Lys Pro Ser Phe Asn Ile Val Pro Leu Thr Ser Arg  
 210 215 220

Val Lys Pro Asp Pro Pro His Ile Lys Asn Leu Ser Phe His Asn Asp  
 225 230 235 240

Asp Leu Tyr Val Gln Trp Glu Asn Pro Gln Asn Phe Ile Ser Arg Cys  
 245 250 255

Leu Phe Tyr Glu Val Glu Val Asn Asn Ser Gln Thr Glu Thr His Asn  
 260 265 270

Val Phe Tyr Val Gln Glu Ala Lys Cys Glu Asn Pro Glu Phe Glu Arg  
 275 280 285

Asn Val Glu Asn Thr Ser Cys Phe Met Val Pro Gly Val Leu Pro Asp  
 290 295 300

Thr Leu Asn Thr Val Arg Ile Arg Val Lys Thr Asn Lys Leu Cys Tyr  
 305 310 315 320

Glu Asp Asp Lys Leu Trp Ser Asn Trp Ser Gln Glu Met Ser Ile Gly  
 325 330 335

Lys Lys Arg Asn Ser Thr Leu Tyr Ile Thr Met Leu Leu Ile Val Pro  
 340 345 350

- 56 -

Val Ile Val Ala Gly Ala Ile Ile Val Leu Leu Leu Tyr Leu Lys Arg  
 355 360 365

Leu Lys Ile Ile Ile Phe Pro Pro Pro Ile Pro Asp Pro Gly Lys Ile Phe  
 370 375 380

Lys Glu Met Phe Gly Asp Gln Asn Asp Asp Thr Leu His Trp Lys Lys  
 385 390 395 400

Tyr Asp Ile Tyr Glu Lys Gln Thr Lys Glu Glu Thr Asp Ser Val Val  
 405 410 415

Leu Ile Glu Asn Leu Lys Lys Ala Ser Gln  
 420 425

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Val Leu Ala Ser Ser Thr Thr Ser Ile His Thr Met Leu Leu Leu  
 5 10 15

Leu Leu Met Leu Phe His Leu Gly Leu Gln Ala Ser Ile Ser  
 20 25 30

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Asp Tyr Lys Asp Asp Asp Asp Lys  
 5

- 57 -

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AGCTTCTAGA ACAGAAGTTC AGCCACCTGT G

31

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AACTCCACCT TCTACACCACT CTGATCTAGA

30

## CLAIMS:

1. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding an haemopoietin receptor from an animal or a derivative of said receptor.
2. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding an animal haemopoietin receptor or a derivative thereof, wherein said receptor:
  - (i) is capable of interaction with IL-13 or its derivatives; and
  - (ii) is capable of interaction with a complex between IL-4 and IL-4 receptor  $\alpha$ -chain.
3. An isolated nucleic acid molecule according to claim 1 or 2 wherein the receptor comprises a derivative of an  $\alpha$ -chain of a haemopoietin receptor capable of interaction with IL-13 with low affinity.
4. An isolated nucleic acid molecule according to claim 1 or 2 wherein the receptor is a derivative of an  $\alpha$ -chain of a haemopoietin receptor capable of interaction with IL-13 with medium to high affinity.
5. An isolated nucleic acid molecule according to claim 1 or 2 encoding a receptor having an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4 or having at least about 50% similarity to all or part thereof.
6. An isolated nucleic acid molecule according to claim 1 or 2 comprising a sequence of nucleotides substantially as set forth in SEQ ID NO:1 or SEQ ID NO:3 or having at least about 50% similarity to all or part thereof.

7. An isolated nucleic acid molecule comprising a sequence of nucleotides which encodes or is complementary to a sequence which encodes an IL-13 receptor  $\alpha$ -chain or a derivative thereof, said nucleic acid molecule having a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:3 or a nucleic acid molecule which encodes a functionally similar IL-13 receptor  $\alpha$ -chain or a derivative thereof and which is capable of hybridising to the nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:3 or a complementary form thereof under low stringency conditions.

8. An isolated nucleic acid molecule comprising a sequence of nucleotides which encodes or is complementary to a sequence which encodes the IL-13 receptor  $\alpha$ -chain or a derivative thereof having an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4 or comprises a nucleotide sequence coding for an amino acid sequence having at least about 50% similarity to the sequence set forth in SEQ ID NO:2 or SEQ ID NO:4 and is capable of hybridising to the sequence set forth in SEQ ID NO:1 or SEQ ID NO:3 under low stringency conditions.

9. An isolated nucleic acid molecule according to claim 1 or 2 or 7 or 8 which encodes a haemopoietin receptor capable of interaction with IL-13 or its derivatives, which interaction is capable of competitive inhibition by IL-4 or a derivative thereof in cells which express an IL-4 receptor  $\alpha$ -chain.

10. A genetic construct comprising a nucleic acid molecule according to claim 1 or 6 or 7 operably linked to a promoter capable of directing expression of said nucleic acid molecule in a host cell.

11. A recombinant polypeptide comprising a sequence of amino acids substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4 or having at least about 50% similarity to all or part thereof, said polypeptide capable of interaction with IL-13 or its derivatives.

12. A recombinant polypeptide according to claim 11 wherein the interaction with IL-13 is competitively inhibited by IL-4 in cells which express an IL-4 receptor  $\alpha$ -chain.

13. A recombinant polypeptide according to claim 11 wherein the interaction with IL-13 is with low affinity.

14. A recombinant polypeptide according to claim 10 wherein the interaction with IL-13 is with medium to high affinity.

15. A recombinant polypeptide according to claim 11 wherein said polypeptide has a molecular weight of from about 50,000 to about 70,000 daltons as determined by Western blot analysis when expressed in COS cells.

16. A recombinant polypeptide having at least two of the following characteristics:

- (i) comprises an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4 or having at least about 50% similarity to all or part thereof;
- (ii) is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:3 or having at least about 50% similarity to all or part thereof;
- (iii) interacts with IL-13 or its derivatives with at least low affinity; and
- (iv) has a molecular weight of from about 50,000 to about 70,000 daltons as determined by Western blot analysis when expressed in COS cells.

17. A recombinant polypeptide having at least three of the following characteristics:

- (i) comprises an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4 or having at least about 50% similarity to all or part thereof;

- (ii) is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:3 or having at least about 50% similarity to all or part thereof;
- (iii) interacts with IL-13 or its derivatives with at least low affinity;
- (iv) has a molecular weight of from about 50,000 to about 70,000 daltons as determined by Western blot analysis when expressed in COS cells;
- (v) comprises an amino acid sequence derived from IL-4 receptor  $\alpha$ -chain; and
- (vi) is capable of interaction with IL-13 which is competitively inhibited by IL-4 in cells which express an IL-4 receptor  $\alpha$ -chain.

18. An antibody to the recombinant polypeptide according to claim 16 and 17.

19. An antibody according to claim 16 wherein said antibody is a monoclonal antibody.

20. A hybrid haemopoietin receptor capable of interaction with at least two cytokines wherein at least one of said cytokines is IL-13 or its derivatives and wherein said hybrid receptor comprises an amino acid sequence which includes all or part of the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:4.

21. A hybrid haemopoietin receptor capable of high affinity interaction with at least one cytokine wherein at least one of said cytokines is IL-13 or its derivatives and wherein said hybrid receptor comprises an amino acid sequence which includes all or part of the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:4.

22. A hybrid haemopoietic receptor according to claim 18 capable of interaction with IL-4.

23. A hybrid haemopoietin receptor according to claim 21 capable of interaction with a cytokine selected from IL-2, IL-5, IL-7, IL-9 and IL-15.

24. A pharmaceutical composition comprising a recombinant polypeptide according to claim 16 or 17 and one or more pharmaceutically acceptable carriers and/or diluents.

25. A genetic pharmaceutical composition comprising a nucleic acid molecule according to claim 1 or 2 or 7 or 8 and one or more genetically acceptable carriers and/or diluents.

26. A method of treatment in an animal comprising administering to said animal a treatment effective amount of a recombinant polypeptide according to claim 16 or 17

27. A method of treating asthma, allergy or a condition exacerbated by IgE production in an animal comprising administering to said animal a treatment of an effective amount of a recombinant polypeptide according to claim 16 or 17.

28. A method of producing a recombinant polypeptide having at least two of the following characteristics:

- (i) comprises an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4 or having at least about 50% similarity thereto;
- (ii) is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:3 or having at least about 50% similarity thereto;
- (iii) interacts with IL-13 or its derivatives with at least low affinity; and
- (iv) has a molecular weight of from about 50,000 to about 70,000 daltons as determined by Western blot analysis when expressed in COS cells,

said method comprising culturing cells comprising the genetic construct according to claim 10 for a time and under conditions sufficient to express the nucleic acid molecule in said genetic construct to produce a recombinant polypeptide and isolating said recombinant polypeptide.

29. A method of producing a recombinant polypeptide having at least three of the following characteristics:

- (i) comprises an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4 or having at least about 50% similarity to all or part thereof;
- (ii) is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:3 or having at least about 50% similarity to all or part thereof;
- <sup>1</sup> (iii) interacts with IL-13 or its derivatives with at least low affinity;
- (iv) has a molecular weight of from about 50,000 to about 70,000 daltons as determined by Western blot analysis when expressed in COS cells;
- (v) comprises an amino acid sequence derived from IL-4 receptor  $\alpha$ -chain; and
- (vi) is capable of interaction with IL-13 which is competitively inhibited by IL-4 in cells which express an IL-4 receptor  $\alpha$ -chain.

said method comprising culturing cells comprising the genetic construct according to claim 10 for a time and under conditions sufficient to express the nucleic acid molecule in said genetic construct to produce a recombinant polypeptide and isolating said recombinant polypeptide.

30. Animal cells which express the recombinant polypeptide produced by the method according to claim 28 and 29.

31. A chimeric protein comprising a first portion capable of interaction with IL-13 or its derivatives and a second portion derived from a haemopoietin receptor, a receptor tyrosine kinase, a TNF/NGF receptor or a G protein coupled receptor.

32. A chimeric protein according to claim 31 wherein the second portion comprises all or a functional portion of IL-13 binding protein, IL-4 receptor  $\alpha$ -chain, IL-2 receptor  $\gamma$ -chain or a receptor for a cytokine implicated in asthma or allergy.

33. A method for monitoring the level of IL-4 in a biological sample said method comprising incubating said biological sample with cells which express NR4 and IL-4 receptor  $\alpha$ -chain together with an effective amount of IL-13 to competitively inhibit IL-4 binding to its receptor and determining the extent of competitive inhibition.

34. A method for monitoring the level of IL-13 in a biological sample said method comprising incubating said biological sample with cells which express NR4 and IL-4 receptor  $\alpha$ -chain together with an effective amount of IL-4 to competitively inhibit IL-13 binding to its receptor and determining the extent of competitive inhibition

35. A method according to claim 33 or 34 wherein the cytokines are labelled with a reporter molecule.

**ABSTRACT**

The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.

63  
62  
60  
59  
58  
57  
56  
55  
54  
53  
52  
51  
50

1/24

2/24	3/24
4/24	5/24
6/24	7/24

Fig. 1

2/24

- 60	tgaaaagatagaataatggcctcgta								
1	<u>ATGGCGCGGCCAGCGCTGCTGGCGAG</u>								
1	M	A	R	P	A	L	L	G	E
61	<u>GGCCAAGTTGCCGCACAGAACAGAAGTT</u>								
21	G	Q	V	A	A	A	T	E	V
121	GAAAATCTCTGCACGATAATATGGACG								
41	E	N	L	C	T	I	I	W	T
181	ACTCTCAGATATTTAGTCACTTGAT								
61	T	L	R	Y	F	S	H	F	D
241	CATCGTAAAGAGGAATTACCCCTGGAT								
81	H	R	K	E	E	L	P	L	D
301	AGTGCCAATGAAAGTGAGAAGCCTAGC								
101	S	A	N	E	S	E	K	P	S
361	<u>GGTGATCCTGAGTCCGCTGTGACTGAG</u>								
121	G	D	P	E	S	A	V	T	E
421	AAGTGTCCCTGGCTCCCTGGAAAGGAAT								
141	K	C	S	W	L	P	G	R	N

Fig. 1(i)

3/24

ccgaattcggcacgagccgaggcgagggcctgc

CTGTTGGTGCTGCTACTGTGGACCGCCACCGTG

L L V L L L W T A T V

CAGCCACCTGTGACGAATTGAGCGTCTCTGTQ

Q, P P V T N L S V S V

TGGAGTCCTCCTGAAGGAGGCCAGTCCAAATTGC

W S P P E G A S P N C

GACCAACAGGATAAGAAAATTGCTCCAGAAACT

D Q Q D K K I A P E T

GAGAAAATCTGTCTGCAGGTGGGCTCTCAGTGT

E K I C L Q V G S Q C

CCTTTGGTGAAAAAGTCATCTCACCCCCCTGAA

P L V K K C I S P P E

CTCAAGTGCATTTGGCATAACCTGAGCTATATG

L K C I W H N L S Y M

ACAAGCCCTGACACACACTATACTCTGTACTAT

T S P D T H Y T L Y Y

*Fig. 1(ii)*

4/24

481	TGGTACAGCAGCCTGGACAAAAGTCGT
161	W Y S S L E K S R
541	ATTGCTTGTTCCTTAAATTGACTAAA
181	I A C S F K L T K
601	ATAATGGTCAAGGATAATGCTGGGAAA
201	I M V K D N A G K
661	TCCTATGTGAAACCTGATCCTCCACAT
221	S Y V K P D P P H
721	TTAGTGCAGTGGAAGAATCCACAAAAT
241	L V Q W K N P Q N
781	GTCAATAATACTCAAACCGACCGACAT
261	V N N T Q T D R H
841	AATTCCGAATCTGATAGAACATGGAG
281	N S E S D R N M E
901	GCCGACGCTGTCTACACAGTCAGAGTA
301	A D A V Y T V R V
961	AACAAACTGTGGAGTGATTGGAGTGAA
321	N K L W S D W S E

Fig. 1(iii)

5/24

CAATGTGAAAACATCTATAGAGAAGGTCAACAC  
Q C E N I Y R E G Q H

GTGGAACTAGTTTGAACATCAGAACGTTCAA  
V E P S F E H Q N V Q

ATTAGGCCATCCTGCAAAATAGTGTCTTTA  
I R P S C K I V S L T

ATTAAACATCTCTCCTCAAAATGGTGCCTTA  
I K H L L L K N G A L

TTTAGAACAGATGCTTAACCTATGAAGTGGAG  
F R S R C L T Y E V E

AATATTTAGAGGTTGAAGAGGACAAATGCCAG  
N I L E V E E D K C Q

GGTACAAGTTGTTCCAACCTCCCTGGTGTCTT  
G T S C F Q L P G V L

AGAGTCAAAACAAACAAGTTATGCTTGATGAC  
R V K T N K L C F D D

GCACAGAGTATAGGTAAGGAGCAAAACTCCACC  
A Q S I G K E Q N S T

Fig. 1(iv)

6/24

1021	TTCTACACCACCATGTTACTCACCAATT
341	F Y T T M L L T I
1081	CTTTTATACCTGAAAAGGCTTAAGATC
361	L F Y L K R L K I
1141	ATTTTAAAGAAATGTTGGAGACCAG
381	I F K E M F G D Q
1201	ATCTATGAGAAACAATCCAAAGAAGAA
401	I Y E K Q S K E E
1261	AAAGCAGCTCCTTGAtggggagaagtg
421	K A A P *
1321	gatttattgcattctccatttgttatac
1381	cttgaaaaacaggcagctcctaagagc
1441	ccaaacccaaaggagctccttccaaga
1501	ccctaaaagcagatgtttgccaaatc
1561	accatcaattcatctaattcaggaattg

Fig. 1(v)

7/24

CCAGTCTTGTGCGCAGTGGCAGTCATAATCCTC  
P V F V A V A V I I L

ATTATATTCCTCCAATTCTGATCCTGGCAAG!  
I I F P P I P D P G K

AATGATGATACCCCTGCACTGGAAGAACTATGAC  
N D D T L H W K K Y D

ACGGATTCTGTAGTGCTGATAGAAAACCTGAAG  
T D S V V L I E N L K

atttcttcttgcccttaatgtgaccctgtcaa

tggggacttgttaaatagaaactgaaactact  
cacaggtcttgatgtgactttgcattgaaaac  
aaagcaagagtcttcgttccttgttccaaat  
cccaaactagaggacaaagacaaggggacaatg  
tcatggcttcctaaggaatctctgcttgctctg

*Fig. 1(vi)*

8/24

## NR4 EXPRESSION IN MOUSE TISSUES




Fig. 2

9/24




Fig. 3(A)




Fig. 3(B)




Fig. 3(C)

10/24




Fig.4(A)






Fig.4(B)



11/24





Fig. 5(A)



12/24


CROSS-SPECIES CONSERVATION OF THE NR-4 (IL-13R  $\alpha$ )  
GENE

Fig. 6

(major)

DYKDD	DDYKD	DDES R	TEVQP	PVTXL	SV
1	5	10	15	20	25

(minor)

ASIIS	SDYKD	DDES R	TEVQP	PVTXL	SV
1	5	10	15	20	25

13/24

14/24	15/24
16/24	17/24
18/24	19/24
20/24	21/24
22/24	23/24

Fig. 7

14/24

H		gagtctaacacggaccaaggagttAAC		
M	- 60	tgaaaagatagaataatggcctcggtgc		
H		M E W P A R L C G ATGGAGTGGCCGGCGCGGGCTCTGGCGGGC		
		* * * * *		
M	1	ATGGCGCGGCCAGCGCTGCTGGCGAGC		
M	1	M A R P A L L G E		
H		G G G G A P T E T		
H		GGGGGCGGGGCGCGCCTACGGAAACTC		
		* * * *		
M	61	GGCCAAGTTGCCGCGGCCACAGAAGTTC		
M	21	G Q V A A A T E V		
H		E N L C T V I W T		
H		GAAAACCTCTGCACAGTAATATGGACAT		
		* * * * *		
M	121	GAAAATCTCTGCACGATAATATGGACGT		
M	41	E N L C T I I W T		
H		S L W Y F S H F G		
H		AGTCTATGGTATTTAGTCATTTGGCG		
		* * * * *		
M	181	ACTCTCAGATATTTAGTCACTTGATG		
M	61	T L R Y F S H F D		

Fig. 7(i)

15/24

	acgtgcggccgggttccgaggcgagaggctgc
	.....
	cgaattcggcacgagccgaggcgagggcctgc
	L W A L L L C A G G G G
	TGTGGGCGCTGCTGCTCTGCGCCGGCGGGGGGGC
	* * * *
	TGTTGGTGCTGCTACTGTGGACCGCCACCGTG - - -
	L L V L L L W T A T V -
	Q P P V T N L S V S V
	AGCCACCTGTGACAAATTGAGTGTCTCTGTT
	* * * * * * * * * * * *
	AGCCACCTGTGACGAATTGAGCGTCTCTGTC
	Q P P V T N L S V S V
	W N P P E G A S S N C
	GGAATCCACCCGAGGGAGCCAGCTCAAATTGT
	* * * * * * * * * *
	GGAGTCCTCCTGAAGGAGCCAGTCCAAATTGC
	W S P P E G A S P N C
	D K Q D K K I A P E T
	ACAAACAAGATAAGAAAATAGCTCCGGAAACT
	* * * * * * * * * *
	ACCAACAGGATAAGAAAATTGCTCCAGAAACT
	D Q Q D K K I A P E T

Fig. 7(ii)

16/24

H	R	R	S	I	E	V	P	L	N
H	CGTCGTTCAATAGAAGTACCCCTGAATG								
	*		*		*		*		*
M	241	CATCGTAAAGAGGAATTACCCCTGGATG							
M	81	H R K E E L P L D							
H	S	T	N	E	S	E	K	P	S
H	AGCACCAATGAGAGTGGAGAAGCCTAGCA								
	*	*	*	*	*	*	*	*	*
M	301	AGTGCCAATGAAAGTGGAGAAGCCTAGCC							
M	101	S A N E S E K P S							
H	G	D	P	E	S	A	V	T	E
H	GGTGATCCTGGAGTCTGCTGTGACTGAAC								
	*	*	*	*	*	*	*	*	*
M	361	GGTGATCCTGGAGTCGGCTGTGACTGAGC							
M	121	G D P E S A V T E							
H	K	C	S	W	L	P	G	R	N
H	AAAGTGTCTGGCTCCCTGGAAAGGAATA								
	*	*	*	*	*	*	*	*	*
M	421	AAAGTGTCTGGCTCCCTGGAAAGGAATA							
M	141	K C S W L P G R N							
H	W	H	R	S	L	E	K	I	H
H	TGGCACAGAAGCCTGGAAAAAATTCATC								

Fig. 7(iii)

17/24

E	R	I	C	L	Q	V	G	S	Q	C
AGAGGATTGTCTGCAAGTGGGGTCCCAGTGT										
*	*	*	*	*	*	*	*	*	*	*
AGAAAATCTGTCTGCAGGTGGCTCTCAGTGT										
E	K	I	C	L	Q	V	G	S	Q	C
I' L V E K C I S P P E										
TTTTGGTTGAAAAATGCATCTCACCCCCAGAA										
*	*	*	*	*	*	*	*	*	*	*
CTTGGTGAAAAAGTGCATCTCACCCCTGAA										
P	L	V	K	K	C	I	S	P	P	E
L	Q	C	I	W	H	N	L	S	Y	M
TTCAATGCATTTGGCACAACCTGAGCTACATG										
*	*	*	*	*	*	*	*	*	*	*
TCAAGTGCATTTGGCATAACCTGAGCTATATG										
L	K	C	I	W	H	N	L	S	Y	M
T	S	P	D	T	N	Y	T	L	Y	Y
CCAGTCCCACACTAACTATACTCTACTAT										
*	*	*	*	*	*	*	*	*	*	*
CAAGCCCTGACACACACTATACTCTGTACTAT										
T	S	P	D	T	H	Y	T	L	Y	Y
Q	C	E	N	I	F	R	E	G	Q	Y
AATGTGAAAACATCTTAGAGAAGGCCAATAC										

Fig. 7(iv)

18/24

		*	*	*	*	*	*
M	481	TGGTACAGCAGCCTGGAGAAAAGTCGTC					
M	161	W Y S S L E K S R					
H		F G C S F D L T K					
H		TTTGGTTGTTCTTGTGATCTGACCAAAG	*	*	*	*	*
M	541	ATTGCTTGTTCTTAAATTGACTAAAG					
M	181	I A C S F K L T K					
H		Q I M V K D N A G					
H		CAAATAATGGTCAAGGATAATGCAGGAA	*	*	*	*	*
M	601	CAAATAATGGTCAAGGATAATGCTGGGA					
M	201	Q I M V K D N A G					
H		T S R V K P D P P					
H		ACTTCCC GTGTGAAACCTGATCCTCCAC	*	*	*	*	*
M	661	ACTTCCTATGTGAAACCTGATCCTCCAC					
M	221	T S Y V K P D P P					
H		L Y V Q W E N P Q					
H		CTATATGTGCAATGGGAGAATCCACAGA	*	*	*	*	*
M	721	TTATTAGTGCAGTGGAAAGAATCCACAAA					
M	241	L L V Q W K N P Q					

Fig. 7(v)

19/24

*	*	*	*	*	*	*	*	*	*	*	*
AATGTGAAAACATCTATAGAGAAGGTCAACAC											
Q	C	E	N	I	Y	R	E	G	Q	H	
V	K	D	S	S	F	E	Q	H	S	V	
TGAAGGATTCCAGTTTGAACAACACAGTGTC											
*	*	*	*	*	*	*	*	*	*	*	!
TGGAACCT - - AGTTTGAAACATCAGAACG TT											
V	E	P	-	S	F	E	H	Q	N	V	
K	I	K	P	S	F	N	I	V	P	L	
AAATTAAACCACATCCTCAATATAGTGCCTTTA											
*	*	*	*	*	*	*	*	*	*	*	
AAATTAGGCCATCCTGC AAAATAGTGTCTTTA											
K	I	R	P	S	C	K	I	V	S	L	
H	I	K	N	L	S	F	H	N	D	D	
ATATTAAAAACCTCTCCTCCACAATGATGAC											
*	*	*	*	*	*	*	*	*	*	*	
ATATTAAACATCTCTCCTCAAAATGGTGCC											
H	I	K	H	L	L	L	K	N	G	A	
N	F	I	S	R	C	L	F	Y	E	V	
ATTTTATTAGCAGATGCCTATTATGAAGTA											
*	*	*	*	*	*	*	*	*	*	*	
ATTTAGAACAGATGCTTAACCTATGAAGTG											
N	F	R	S	R	C	L	T	Y	E	V	

Fig. 7(vi)

20/24

H		E	V	N	N	S	Q	T	E	T
H		GAAGTCAATAAACAGCCAAACTGAGACAC								
		*	*	*	*	*	*	*		
M	781	GAGGTCAATAATACTCAAACCGACCGAC								
M	261	E	V	N	N	T	Q	T	D	R
		*	*	*	*	*	*	*	*	
H		E	N	P	E	F	E	R	N	V
H		GAGAATCCAGAATTGAGAGAAATGTGG								
		*	*	*	*	*	*	*		
M	841	CAGAATTCCGAATCTGATAGAACATGG								
M	281	Q	N	S	E	S	D	R	N	M
		*	*	*	*	*	*	*	*	
H		L	P	D	T	L	N	T	V	R
H		CTTCCTGATACTTTGAACACACAGTCAGAA								
		*	*	*	*	*	*	*	*	
M	901	CTTGCCGACGCTGTCTACACAGTCAGAG								
M	301	L	A	D	A	V	Y	T	V	R
		*	*	*	*	*	*	*	*	
H		D	D	K	L	W	S	N	W	S
H		GATGACAAACTCTGGAGTAATTGGAGCC								
		*	*	*	*	*	*	*	*	
M	961	GACAACAAACTGTGGAGTGATTGGAGTG								
M	321	D	N	K	L	W	S	D	W	S
		*	*	*	*	*	*	*	*	
H		T	L	Y	I	T	M	L	L	I
H		ACACTCTACATAACCATGTTACTCATTG								

Fig. 7(vii)

21/24

H	N	V	F	Y	V	Q	E	A	K	C
ATAATGTTTCTACGTCCAAGAGGGCTAAATGT										
*	*	*	*	*	*	*	*	*	*	*
ATAATATTTAGAGGTGAAGAGGGACAAATGC										
H	N	I	L	E	V	E	E	D	K	C
										1
E	N	T	S	C	F	M	V	P	G	V
AGAATACATCTGTTCATGGTCCCTGGTGT										
*	*	*	*	*	*	*	*	*	*	*
AGGGTACAAGTTGTTCCAACCTCCCTGGTGT										
E	G	T	S	C	F	Q	L	P	G	V
I	R	V	K	T	N	K	L	C	Y	E
TAAGAGTCAAAACAAATAAGTTATGCTATGAG										
*	*	*	*	*	*	*	*	*	*	*
TAAGAGTCAAAACAAACAAGTTATGCTTGAT										
V	R	V	K	T	N	K	L	C	F	D
Q	E	M	S	I	G	K	K	R	N	S
AAGAAATGAGTATAGGTAAGAACGCGCAATTCC										
*	*	*	*	*	*	*	*	*	*	*
AAGCACAGAGTATAGGTAAGGAGCAAAACTCC										
E	A	Q	S	I	G	K	E	Q	N	S
V	P	V	I	V	A	G	A	I	I	V
TTCCAGTCATCGTCGAGGTGCAATCATAGTA										

Fig. 7(viii)

22/24

		*	*	*	*	*	*	*
M	1021	ACCTTCTACACCACCATGTTACTCACCA						
M	341	T F Y T T M L L T						
H		L L L Y L K R L K						
H		CTCCTGCTTTACCTAAAAAGGCTCAAGA						
		*	*	*	*	*	*	*
M	1081	CTCCTT TTACCTGAAAAGGCTTAAGA						
M	361	L L F Y L K R L K						
H		K I F K E M F G D						
H		AAGATTTTAAAGAAATGTTGGAGACC						
		*	*	*	*	*	*	*
M	1141	AAGATTTTAAAGAAATGTTGGAGACC						
M	381	K I F K E M F G D						
H		D I Y E K Q T K E						
H		GACATCTATGAGAAAGCAAACCAAGGAGG						
		*	*	*	*	*	*	*
M	1201	GACATCTATGAGAAACAATCCAAAGAAG						
M	401	D I Y E K Q S K E						
H		K K A S Q *						
H		AAGAAAGCCTCTCAGTGAtggagataat						
		*	*	*				
M	1261	AAGAAAGCAGCTCCTTGAtggggagaag						
M	421	K K A A P *						

Fig. 7(ix)

23/24

	*	*	*	*	*	*	*	*
TTCCAGTCTTGTCGCAGTGGCAGTCATAATC								
I P V F V A V A V I I								
TTATTATATTCCCTCCAATTCCCTGATCCTGGC								
I I I F P P I P D P G								
TCATTATATTCCCTCCAATTCCCTGATCCTGGC								
I I I F P P I P D P G								
Q N D D T L H W K K Y								
AGAACATGATGATACTCTGCACTGGAAGAAGTAC								
*	*	*	*	*	*	*	*	*
AGAACATGATGATACTCTGCACTGGAAGAAGTAT								
Q N D D T L H W K K Y								
E T D S V V L I E N L								
AAACCGACTCTGTAGTGTGCTGATAGAAAACCTG								
*	*	*	*	*	*	*	*	*
AAACGGATTCTGTAGTGTGCTGATAGAAAACCTG								
E T D S V V L I E N L								
ttattttacccactgtgaccccttgagaaga								
tgatttcttcttgcccttcaatgtgaccctgt								

Fig. 7(x)

24/24




Fig. 8




Fig. 9

## COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

Inventor's Declaration to PCT International Office

11373

As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: "A novel haemopoietin receptor and genetic sequences encoding same"

the specification of which (check only one item below):

is attached hereto.

was filed as United States application

Serial No. \_\_\_\_\_

on 22 April 1998 \_\_\_\_\_

and was amended

on \_\_\_\_\_ (if applicable).

was filed as PCT international application

Number PCT/AU96/00668 \_\_\_\_\_on 23 October 1998 \_\_\_\_\_

and was amended under PCT Article 19

on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

## PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY & PCT NUMBER PCT I	APPLICATION NUMBER	DATE OF FILING (day month year)	PRIORITY CLAIMED UNDER 35 USC 119
Australia	PN 6135	23 October 1995	<input type="checkbox"/> YES <input type="checkbox"/> NO
Australia	PN 7276	22 December 1995	<input type="checkbox"/> YES <input type="checkbox"/> NO
Australia	PO 2208	9 September 1996	<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under Title 35, United States Code, §120 (or similar United States applications) or PCT international applications) designating the United States of America that are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that, those prior applications) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(d) which occurred before the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER  
35 U.S.C. 120:

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:  
Kenneth D. Murphy, Reg. No. 22,002; Franko L. Preiser, Reg. No. 18,827; William C. Koch, Reg. No. 24,972;  
Stephen J. Senseny, Reg. No. 34,223; Frank S. DiGiglio, Reg. No. 31,346; Paul J. Esposito, Jr., Reg. No. 30,745;  
John S. Senseny, Reg. No. 28,757; Mark J. Cohen, Reg. No. 32,211; Richard L. Catania, Reg. No. 32,608 and  
Donald T. Black, Reg. No. 27,988.

Send Correspondence to:				Direct Telephone Call to: Name and telephone number
Scully, Scott, Murphy & Presser 400 Garden City Plaza Garden City, NY 11530				Geopold Presser (516) 742-4343
2011	FULL NAME OF INVENTOR <b>WILLSON</b>	FAMILY NAME <b>Tracy</b>	FIRST GIVEN NAME <b>Tracy</b>	SECOND GIVEN NAME
	RESIDENCE & CITY/NAME <b>North Balwyn</b>	CITY <b>Victoria, Australia</b>	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS <b>26 Fortune Avenue</b>	CITY <b>North Balwyn, Victoria</b>	STATE & ZIP CODE, COUNTRY <b>3104, Australia</b>	
2012	FULL NAME OF INVENTOR <b>NICOLA</b>	FAMILY NAME <b>Nicos</b>	FIRST GIVEN NAME <b>Nicos</b>	SECOND GIVEN NAME <b>A</b>
	RESIDENCE & CITY/NAME <b>Mont Albert</b>	CITY <b>Victoria, Australia</b>	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS <b>56 Churchill Avenue</b>	CITY <b>Mont Albert, Victoria</b>	STATE & ZIP CODE, COUNTRY <b>3127, Australia</b>	
2013	FULL NAME OF INVENTOR <b>HILTON</b>	FAMILY NAME <b>Douglas</b>	FIRST GIVEN NAME <b>Douglas</b>	SECOND GIVEN NAME <b>J.</b>
	RESIDENCE & CITY/NAME <b>Warrandyte</b>	CITY <b>Victoria, Australia</b>	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS <b>244 Research Road</b>	CITY <b>Warrandyte, Victoria</b>	STATE & ZIP CODE, COUNTRY <b>3113, Australia</b>	



I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201 <i>W.A. Wiles</i>	SIGNATURE OF INVENTOR 202 <i>Heon J. Almeida</i>	SIGNATURE OF INVENTOR 203 <i>_____</i>
DATE 09/06/1998	DATE June 8, 1998	DATE 7/6/98

[ ] Signature for fourth and subsequent joint inventors.  
Number of pages added .

FAMILY NAME OF INVENTOR	FAMILY NAME NETCALF	FIRST GIVEN NAME Donald	SECOND GIVEN NAME
RESIDENCE & CITIZENSHIP	CITY Balwyn	STATE OR FOREIGN COUNTRY Victoria, Australia	COUNTRY OF CITIZENSHIP Australia
POST OFFICE ADDRESS	POST OFFICE ADDRESS 268 Union Road	CITY Balwyn, Victoria	STATE & ZIP CODE/COUNTRY 3103, Australia
FAMILY NAME OF INVENTOR	FAMILY NAME ZHANG	FIRST GIVEN NAME Jian	SECOND GIVEN NAME Guo
RESIDENCE & CITIZENSHIP	CITY Hoppers Crossing	STATE OR FOREIGN COUNTRY Victoria, Australia	COUNTRY OF CITIZENSHIP Republic of China
POST OFFICE ADDRESS	POST OFFICE ADDRESS 3 Kerri Crescent	CITY Hoppers Crossing, Victoria	STATE & ZIP CODE/COUNTRY 3029, Australia
FAMILY NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
FAMILY NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
FAMILY NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
FAMILY NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
FAMILY NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 204  JUL 5 1998	SIGNATURE OF INVENTOR 205  9/6/1998	SIGNATURE OF INVENTOR 206
SIGNATURE OF INVENTOR 207	SIGNATURE OF INVENTOR 208	SIGNATURE OF INVENTOR 209
NAME	DATE	DATE

PATENTS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant(s):** Tracy A. Wilson, et al.

**Examiner:** Unassigned

**Serial No:** Unassigned

**Art Unit:** Unassigned

**Filed:** Herewith

**Docket:** 11373A

**For:** A NOVEL HAEMOPOIETIN RECEPTOR **Date:** October 13, 2000  
AND GENETIC SEQUENCES ENCODING  
SAME

Assistant Commissioner for Patents  
United States Patent and Trademark Office  
Washington, D.C. 20231

**REQUEST TO USE COMPUTER READABLE FORM OF SEQUENCE  
LISTING FROM ANOTHER APPLICATION UNDER 37 C.F.R. §1.821(e)**

Sir:

The computer readable form of the Sequence Listing in the above-identified patent application is identical to that filed with the parent case, U.S. Serial Number: 09/051,843 filed on October 23, 1996. In accordance with 37 C.F.R. §1.821(e), Applicants respectfully request that the computer readable form filed in Application Number 09/051,843 be used as the computer readable form in the above-identified application.

---

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

**"Express Mail" mailing label number:** EL680252395US

**Date of Deposit:** October 13, 2000

I hereby certify that this New Patent Application and Fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.


**Dated:** October 13, 2000

  
Mishelle Mustafa

It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form used in the above-identified application. A paper copy of the Sequence Listing is included herewith.

Accordingly, the present application is in condition for allowance and such action is earnestly solicited.

Respectfully submitted,



Leopold Presser  
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

PIB:bb

SEQUENCE LISTING

<110> Willson, Tracy  
Nicola, Nicos A.  
Hilton, Douglas J.  
Metcalf, Donald  
Zhang, Jian G.

<120> NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES  
ENCODING SAME

<130> Davies cc

<140> 09/051,843  
<141> 1998-06-29

<160> 8

<170> PatentIn Ver. 2.0

<210> 1  
<211> 1383  
<212> DNA  
<213> nuc. & predicted a.a. seq. of mNR4

<220>  
<221> CDS  
<222> (61)..(1338)

<220>  
<221> unsure  
<222> (121)  
<223> n=authors are unsure of exact sequence in this  
region

<220>  
<221> unsure  
<222> (122)  
<223> n=authors are unsure of exact sequence in this  
region

<220>  
<221> unsure  
<222> (123)  
<223> n=authors are unsure of exact sequence in this  
region

<220>  
<221> unsure  
<222> (640)  
<223> n=authors are unsure of exact sequence in this  
region

<220>  
<221> unsure  
<222> (641)  
<223> n=authors are unsure of exact sequence in this region

<220>  
<221> unsure  
<222> (642)  
<223> n=authors are unsure of exact sequence in this region

<400> 1  
tgaaaagata gaataaatgg cctcgtgccg aattcggcac gagccgaggc gagggcctgc 60

atg ggc cgg cca ggc ctg ctg ggc gag ctg ttg gtg ctg cta ctg tgg 108  
Met Ala Arg Pro Ala Leu Leu Gly Glu Leu Leu Val Leu Leu Leu Trp  
1 5 10 15

acc gcc acc gtg nnn ggc caa gtt gcc ggc gcc aca gaa gtt cag cca 156  
Thr Ala Thr Val Xaa Gly Gln Val Ala Ala Ala Thr Glu Val Gln Pro  
20 25 30

cct gtg acg aat ttg agc gtc tct gtc gaa aat ctc tgc acg ata ata 204  
Pro Val Thr Asn Leu Ser Val Ser Val Glu Asn Leu Cys Thr Ile Ile  
35 40 45

tgg acg tgg agt cct cct gaa gga gcc agt cca aat tgc act ctc aga 252  
Trp Thr Trp Ser Pro Pro Glu Gly Ala Ser Pro Asn Cys Thr Leu Arg  
50 55 60

tat ttt agt cac ttt gat gac caa cag gat aag aaa att gct cca gaa 300  
Tyr Phe Ser His Phe Asp Asp Gln Gln Asp Lys Ile Ala Pro Glu  
65 70 75 80

act cat cgt aaa gag gaa tta ccc ctg gat gag aaa atc tgt ctg cag 348  
Thr His Arg Lys Glu Leu Pro Leu Asp Glu Lys Ile Cys Leu Gln  
85 90 95

gtg ggc tct cag tgt agt gcc aat gaa agt gag aag cct agc cct ttg 396  
Val Gly Ser Gln Cys Ser Ala Asn Glu Ser Glu Lys Pro Ser Pro Leu  
100 105 110

gtg aaa aag tgc atc tca ccc cct gaa ggt gat cct gag tcc gct gtg 444  
Val Lys Lys Cys Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala Val  
115 120 125

act gag ctc aag tgc att tgg cat aac ctg agc tat atg aag tgt tcc 492  
Thr Glu Leu Lys Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser  
130 135 140

tgg ctc cct gga agg aat aca aac cct gac aca cac tat act ctg tac		540
Trp Leu Pro Gly Arg Asn Thr Ser Pro Asp Thr His Tyr Thr Leu Tyr		
145 150 155 160		
tat tgg tac agc agc ctg gag aaa agt cgt caa tgt gaa aac atc tat		588
Tyr Trp Tyr Ser Ser Leu Glu Lys Ser Arg Gln Cys Glu Asn Ile Tyr		
165 170 175		
aga gaa ggt caa cac att gct tgt tcc ttt aaa ttg act aaa gtg gaa		636
Arg Glu Gly Gln His Ile Ala Cys Ser Phe Lys Leu Thr Lys Val Glu		
180 185 190		
cct nnn agt ttt gaa cat cag aac gtt caa ata atg gtc aag gat aat		684
Pro Xaa Ser Phe Glu His Gln Asn Val Gln Ile Met Val Lys Asp Asn		
195 200 205		
gct ggg aaa att agg cca tcc tgc aaa ata gtg tct tta act tcc tat		732
Ala Gly Lys Ile Arg Pro Ser Cys Lys Ile Val Ser Leu Thr Ser Tyr		
210 215 220		
gtg aaa cct gat cct cca cat att aaa cat ctt ctc ctc aaa aat ggt		780
Val Lys Pro Asp Pro Pro His Ile Lys His Leu Leu Leu Lys Asn Gly		
225 230 235 240		
gcc tta tta gtg cag tgg aag aat cca caa aat ttt aga agc aga tgc		828
Ala Leu Leu Val Gln Trp Lys Asn Pro Gln Asn Phe Arg Ser Arg Cys		
245 250 255		
tta act tat gaa gtg gag gtc aat aat act caa acc gac cga cat aat		876
Leu Thr Tyr Glu Val Glu Val Asn Asn Thr Gln Thr Asp Arg His Asn		
260 265 270		
att tta gag gtt gaa gag gac aaa tgc cag aat tcc gaa tct gat aga		924
Ile Leu Glu Val Glu Asp Lys Cys Gln Asn Ser Glu Ser Asp Arg		
275 280 285		
aac atg gag ggt aca agt tgt ttc caa ctc cct ggt gtt ctt gcc gac		972
Asn Met Glu Gly Thr Ser Cys Phe Gln Leu Pro Gly Val Leu Ala Asp		
290 295 300		
gct gtc tac aca gtc aga gta aga gtc aaa aca aac aag tta tgc ttt		1020
Ala Val Tyr Thr Val Arg Val Arg Val Lys Thr Asn Lys Leu Cys Phe		
305 310 315 320		
gat gac aac aaa ctg tgg agt gat tgg agt gaa gca cag agt ata ggt		1068
Asp Asp Asn Lys Leu Trp Ser Asp Trp Ser Glu Ala Gln Ser Ile Gly		
325 330 335		
aag gag caa aac tcc acc ttc tac acc acc atg tta ctc acc att cca		1116
Lys Glu Gln Asn Ser Thr Phe Tyr Thr Thr Met Leu Leu Thr Ile Pro		
340 345 350		

gtc ttt gtc gca gtg gca gtc ata atc ctc ctt ttt tac ctg aaa agg	1164
Val Phe Val Ala Val Ala Val Ile Ile Leu Leu Phe Tyr Leu Lys Arg	
355 360 365	
ctt aag atc att ata ttt cct cca att cct gat cct ggc aag att ttt	1212
Leu Lys Ile Ile Ile Phe Pro Pro Ile Pro Asp Pro Gly Lys Ile Phe	
370 375 380	
aaa gaa atg ttt gga gac cag aat gat gat acc ctg cac tgg aag aag	1260
Lys Glu Met Phe Gly Asp Gln Asn Asp Asp Thr Leu His Trp Lys Lys	
385 390 395 400	
tat gac atc tat gag aaa caa tcc aaa gaa gaa acg gat tct gta gtg	1308
Tyr Asp Ile Tyr Glu Lys Gln Ser Lys Glu Glu Thr Asp Ser Val Val	
405 410 415	
ctg ata gaa aac ctg aag aaa gca gct cct tgatggggag aagtgtttc	1358
Leu Ile Glu Asn Leu Lys Lys Ala Ala Pro	
420 425	
tttcttgcc tcaatgtgac cctgt	1383

<210> 2  
 <211> 426  
 <212> PRT  
 <213> nuc. & predicted a.a. seq. of mNR4  
  
 <220>  
 <221> unsure  
 <222> (21)  
 <223> authors are unsure about the sequence assignment  
  
 <220>  
 <221> unsure  
 <222> (194)  
 <223> authors are unsure about the sequence assignment  
  
 <400> 2  
 Met Ala Arg Pro Ala Leu Leu Gly Glu Leu Leu Val Leu Leu Trp  
 1 5 10 15  
  
 Thr Ala Thr Val Xaa Gly Gln Val Ala Ala Ala Thr Glu Val Gln Pro  
 20 25 30  
  
 Pro Val Thr Asn Leu Ser Val Ser Val Glu Asn Leu Cys Thr Ile Ile  
 35 40 45  
  
 Trp Thr Trp Ser Pro Pro Glu Gly Ala Ser Pro Asn Cys Thr Leu Arg  
 50 55 60

Tyr	Phe	Ser	His	Phe	Asp	Asp	Gln	Gln	Asp	Lys	Lys	Ile	Ala	Pro	Glu
65					70					75					80
Thr	His	Arg	Lys	Glu	Glu	Leu	Pro	Leu	Asp	Glu	Lys	Ile	Cys	Leu	Gln
			85						90					95	
Val	Gly	Ser	Gln	Cys	Ser	Ala	Asn	Glu	Ser	Glu	Lys	Pro	Ser	Pro	Leu
			100					105					110		
Val	Lys	Cys	Ile	Ser	Pro	Pro	Glu	Gly	Asp	Pro	Glu	Ser	Ala	Val	
	115				120					125					
Thr	Glu	Leu	Lys	Cys	Ile	Trp	His	Asn	Leu	Ser	Tyr	Met	Lys	Cys	Ser
	130					135					140				
Trp	Leu	Pro	Gly	Arg	Asn	Thr	Ser	Pro	Asp	Thr	His	Tyr	Thr	Leu	Tyr
145				150					155					160	
Tyr	Trp	Tyr	Ser	Ser	Leu	Glu	Lys	Ser	Arg	Gln	Cys	Glu	Asn	Ile	Tyr
			165					170					175		
Arg	Glu	Gly	Gln	His	Ile	Ala	Cys	Ser	Phe	Lys	Leu	Thr	Lys	Val	Glu
			180				185						190		
Pro	Xaa	Ser	Phe	Glu	His	Gln	Asn	Val	Gln	Ile	Met	Val	Lys	Asp	Asn
	195					200					205				
Ala	Gly	Lys	Ile	Arg	Pro	Ser	Cys	Lys	Ile	Val	Ser	Leu	Thr	Ser	Tyr
	210				215					220					
Val	Lys	Pro	Asp	Pro	Pro	His	Ile	Lys	His	Leu	Leu	Leu	Lys	Asn	Gly
225				230					235					240	
Ala	Leu	Leu	Val	Gln	Trp	Lys	Asn	Pro	Gln	Asn	Phe	Arg	Ser	Arg	Cys
			245					250				255			
Leu	Thr	Tyr	Glu	Val	Glu	Val	Asn	Asn	Thr	Gln	Thr	Asp	Arg	His	Asn
	260					265					270				
Ile	Leu	Glu	Val	Glu	Glu	Asp	Lys	Cys	Gln	Asn	Ser	Glu	Ser	Asp	Arg
	275					280					285				
Asn	Met	Glu	Gly	Thr	Ser	Cys	Phe	Gln	Leu	Pro	Gly	Val	Leu	Ala	Asp
	290				295					300					
Ala	Val	Tyr	Thr	Val	Arg	Val	Arg	Val	Lys	Thr	Asn	Lys	Leu	Cys	Phe
	305				310					315					320
Asp	Asp	Asn	Lys	Leu	Trp	Ser	Asp	Trp	Ser	Glu	Ala	Gln	Ser	Ile	Gly
			325					330					335		

Lys	Glu	Gln	Asn	Ser	Thr	Phe	Tyr	Thr	Thr	Met	Leu	Leu	Thr	Ile	Pro
						340				345					350
Val	Phe	Val	Ala	Val	Ala	Val	Ile	Ile	Leu	Leu	Phe	Tyr	Leu	Lys	Arg
						355			360		365				
Leu	Lys	Ile	Ile	Ile	Phe	Pro	Pro	Ile	Pro	Asp	Pro	Gly	Lys	Ile	Phe
					370			375		380					
Lys	Glu	Met	Phe	Gly	Asp	Gln	Asn	Asp	Asp	Thr	Leu	His	Trp	Lys	Lys
					385			390		395					400
Tyr	Asp	Ile	Tyr	Glu	Lys	Gln	Ser	Lys	Glu	Glu	Thr	Asp	Ser	Val	Val
					405				410					415	
Leu	Ile	Glu	Asn	Leu	Lys	Lys	Ala	Ala	Pro						
					420			425							

<210> 3  
<211> 1383  
<212> DNA  
<213> IL-13 receptor alpha-chain

<220>  
<221> CDS  
<222> (61)..(1338)

<400> 3  
gagtctaaca cgagccaagg agtttaacac gtgcggccgg gttccgaggg gagaggctgc 60

atg gag tgg ccg gcg cgg ctc tgc ggg ctg tgg gcg ctg ctg ctc tgc	108
Met Glu Trp Pro Ala Arg Leu Cys Gly Leu Trp Ala Leu Leu Leu Cys	
1 5 10 15	

```

gcc ggc ggc ggg ggc ggg ggc ggg ggc gcg cct acg gaa act cag cca 156
Ala Gly Gly Gly Gly Gly Gly Ala Pro Thr Glu Thr Gln Pro
          20      25      30

```

cct gtg aca aat ttg agt gtc tct gtt gaa aac ctc tgc aca gta ata 204  
Pro Val Thr Asn Leu Ser Val Ser Val Glu Asn Leu Cys Thr Val Ile  
35 40 45

```

tgg aca tgg aat cca ccc gag gga gcc agc tca aat tgt agt cta tgg 252
Trp Thr Trp Asn Pro Pro Glu Gly Ala Ser Ser Asn Cys Ser Leu Trp
      50          55          60

```

```

tat ttt agt cat ttt ggc gac aaa caa gat aag aaa ata gct ccg gaa 300
Tyr Phe Ser His Phe Gly Asp Lys Gln Asp Lys Lys Ile Ala Pro Glu
65      70      75      80

```

act cgt cgt tca ata gaa gta ccc ctg aat gag agg att tgt ctg caa	348
Thr Arg Arg Ser Ile Glu Val Pro Leu Asn Glu Arg Ile Cys Leu Gln	
85 90 95	
gtg ggg tcc cag tgt agc acc aat gag agt gag aag cct agc att ttg	396
Val Gly Ser Gln Cys Ser Thr Asn Glu Ser Glu Lys Pro Ser Ile Leu	
100 105 110	
gtt gaa aaa tgc atc tca ccc cca gaa ggt gat cct gag tct gct gtg	444
Val Glu Lys Cys Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala Val	
115 120 125	
act gaa ctt caa tgc att tgg cac aac ctg agc tac atg aag tgt tct	492
Thr Glu Leu Gln Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser	
130 135 140	
tgg ctc cct gga agg aat acc agt ccc gac act aac tat act ctc tac	540
Trp Leu Pro Gly Arg Asn Thr Ser Pro Asp Thr Asn Tyr Thr Leu Tyr	
145 150 155 160	
tat tgg cac aga agc ctg gaa aaa att cat caa tgt gaa aac atc ttt	588
Tyr Trp His Arg Ser Leu Glu Lys Ile His Gln Cys Glu Asn Ile Phe	
165 170 175	
aga gaa ggc caa tac ttt ggt tgt tcc ttt gat ctg acc aaa gtg aag	636
Arg Glu Gly Gln Tyr Phe Gly Cys Ser Phe Asp Leu Thr Lys Val Lys	
180 185 190	
cag tcc agt ttt gaa caa cac agt gtc caa ata atg gtc aag gat aat	684
Gln Ser Ser Phe Glu Gln His Ser Val Gln Ile Met Val Lys Asp Asn	
195 200 205	
gca gga aaa att aaa cca tcc ttc aat ata gtg cct tta act tcc cgt	732
Ala Gly Lys Ile Lys Pro Ser Phe Asn Ile Val Pro Leu Thr Ser Arg	
210 215 220	
gtg aaa cct gat cct cca cat att aaa aac ctc tcc ttc cac aat gat	780
Val Lys Pro Asp Pro His Ile Lys Asn Leu Ser Phe His Asn Asp	
225 230 235 240	
gac cta tat gtg caa tgg gag aat cca cag aat ttt att agc aga tgc	828
Asp Leu Tyr Val Gln Trp Glu Asn Pro Gln Asn Phe Ile Ser Arg Cys	
245 250 255	
cta ttt tat gaa gta gaa gtc aat aac agc caa act gag aca cat aat	876
Leu Phe Tyr Glu Val Glu Val Asn Asn Ser Gln Thr Glu Thr His Asn	
260 265 270	
gtt ttc tac gtc caa gag gct aaa tgt gag aat cca gaa ttt gag aga	924
Val Phe Tyr Val Gln Glu Ala Lys Cys Glu Asn Pro Glu Phe Glu Arg	
275 280 285	

aat gtg gag aat aca tct tgt ttc atg gtc cct ggt gtt ctt cct cct gat	972
Asn Val Glu Asn Thr Ser Cys Phe Met Val Pro Gly Val Leu Pro Asp	
290 295 300	
act ttg aac aca gtc aga ata aga gtc aaa aca aat aag tta tgc tat	1020
Thr Leu Asn Thr Val Arg Ile Arg Val Lys Thr Asn Lys Leu Cys Tyr	
305 310 315 320	
gag gat gac aaa ctc tgg agt aat tgg agc caa gaa atg act ata gtt	1068
Glu Asp Asp Lys Leu Trp Ser Asn Trp Ser Gln Glu Met Thr Ile Val	
325 330 335	
aag aag cgc aat tcc aca ctc tac ata acc atg tta ctc att gtt cca	1116
Lys Lys Arg Asn Ser Thr Leu Tyr Ile Thr Met Leu Leu Ile Val Pro	
340 345 350	
gtc atc gtc gca ggt gca atc ata gta ctc ctg ctt tac cta aaa agg	1164
Val Ile Val Ala Gly Ala Ile Ile Val Leu Leu Leu Tyr Leu Lys Arg	
355 360 365	
ctc aag att att ata ttc cct cca att cct gat cct ggc aag att ttt	1212
Leu Lys Ile Ile Ile Phe Pro Pro Ile Pro Asp Pro Gly Lys Ile Phe	
370 375 380	
aaa gaa atg ttt gga gac cag aat gat gat act ctg cac tgg aag aag	1260
Lys Glu Met Phe Gly Asp Gln Asn Asp Asp Thr Leu His Trp Lys Lys	
385 390 395 400	
tac gac atc tat gag aag caa acc aag gag gaa acc gac tct gta gtg	1308
Tyr Asp Ile Tyr Glu Lys Gln Thr Lys Glu Glu Thr Asp Ser Val Val	
405 410 415	
ctg ata gaa aac ctg aag aaa gcc tct cag tgatggagat aatttat	1358
Leu Ile Glu Asn Leu Lys Ala Ser Gln	
420 425	
tacccact gtgacccctga gaaga	1383

<210> 4  
 <211> 426  
 <212> PRT  
 <213> IL-13 receptor alpha-chain

<400> 4	
Met Glu Trp Pro Ala Arg Leu Cys Gly Leu Trp Ala Leu Leu Leu Cys	
1 5 10 15	
Ala Gly Gly Gly Gly Gly Ala Pro Thr Glu Thr Gln Pro	
20 25 30	

Pro Val Thr Asn Leu Ser Val Ser Val Glu Asn Leu Cys Thr Val Ile  
 35 40 45  
 Trp Thr Trp Asn Pro Pro Glu Gly Ala Ser Ser Asn Cys Ser Leu Trp  
 50 55 60  
 Tyr Phe Ser His Phe Gly Asp Lys Gln Asp Lys Lys Ile Ala Pro Glu  
 65 70 75 80  
 Thr Arg Arg Ser Ile Glu Val Pro Leu Asn Glu Arg Ile Cys Leu Gln  
 85 90 95  
 Val Gly Ser Gln Cys Ser Thr Asn Glu Ser Glu Lys Pro Ser Ile Leu  
 100 105 110  
 Val Glu Lys Cys Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala Val  
 115 120 125  
 Thr Glu Leu Gln Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser  
 130 135 140  
 Trp Leu Pro Gly Arg Asn Thr Ser Pro Asp Thr Asn Tyr Thr Leu Tyr  
 145 150 155 160  
 Tyr Trp His Arg Ser Leu Glu Lys Ile His Gln Cys Glu Asn Ile Phe  
 165 170 175  
 Arg Glu Gly Gln Tyr Phe Gly Cys Ser Phe Asp Leu Thr Lys Val Lys  
 180 185 190  
 Gln Ser Ser Phe Glu Gln His Ser Val Gln Ile Met Val Lys Asp Asn  
 195 200 205  
 Ala Gly Lys Ile Lys Pro Ser Phe Asn Ile Val Pro Leu Thr Ser Arg  
 210 215 220  
 Val Lys Pro Asp Pro Pro His Ile Lys Asn Leu Ser Phe His Asn Asp  
 225 230 235 240  
 Asp Leu Tyr Val Gln Trp Glu Asn Pro Gln Asn Phe Ile Ser Arg Cys  
 245 250 255  
 Leu Phe Tyr Glu Val Glu Val Asn Asn Ser Gln Thr Glu Thr His Asn  
 260 265 270  
 Val Phe Tyr Val Gln Glu Ala Lys Cys Glu Asn Pro Glu Phe Glu Arg  
 275 280 285  
 Asn Val Glu Asn Thr Ser Cys Phe Met Val Pro Gly Val Leu Pro Asp  
 290 295 300

Thr Leu Asn Thr Val Arg Ile Arg Val Lys Thr Asn Lys Leu Cys Tyr  
305 310 315 320

Glu Asp Asp Lys Leu Trp Ser Asn Trp Ser Gln Glu Met Thr Ile Val  
325 330 335

Lys Lys Arg Asn Ser Thr Leu Tyr Ile Thr Met Leu Leu Ile Val Pro  
340 345 350

Val Ile Val Ala Gly Ala Ile Ile Val Leu Leu Leu Tyr Leu Lys Arg  
355 360 365

Leu Lys Ile Ile Ile Phe Pro Pro Ile Pro Asp Pro Gly Lys Ile Phe  
370 375 380

Lys Glu Met Phe Gly Asp Gln Asn Asp Asp Thr Leu His Trp Lys Lys  
385 390 395 400

Tyr Asp Ile Tyr Glu Lys Gln Thr Lys Glu Glu Thr Asp Ser Val Val  
405 410 415

Leu Ile Glu Asn Leu Lys Lys Ala Ser Gln  
420 425

<210> 5

<211> 30

<212> PRT

<213> signal sequence of murine IL-3

<400> 5

Met Val Leu Ala Ser Ser Thr Thr Ser Ile His Thr Met Leu Leu Leu  
1 5 10 15

Leu Leu Met Leu Phe His Leu Gly Leu Gln Ala Ser Ile Ser  
20 25 30

<210> 6

<211> 8

<212> PRT

<213> N-terminal FLAG epitope-tag

<400> 6

Asp Tyr Lys Asp Asp Asp Lys  
1 5

<210> 7

<211> 31

<212> DNA

<213> Oligo 1478 5'

<400> 7

agcttctaga acagaaggta agccacacctgt g

31

<210> 8

<211> 30

<212> DNA

<213> Oligo 1480 5'

<400> 8

aactccacct tctacaccac ctgatctaga

30